ICD-10-PCS 3E0 Administration: Physiological Systems and Anatomical Regions Introduction

The ICD-10-PCS root operation Introduction (code starting with 3E0) involves the purposeful placement of a therapeutic, diagnostic, or other substance into a physiological system or anatomical region. It falls under the Administration section and is used to specify how and where substances are delivered into the body.

This operation covers a wide variety of substances introduced into numerous body regions via different approaches. For example, codes such as 3E00X05 represent the introduction of other antineoplastics into skin and mucous membranes via an external approach, while 3E01305 refers to delivering other antineoplastic substances into subcutaneous tissue through a percutaneous approach. Similarly, the administration of insulin into the peripheral vein can be coded with 3E033VG via a percutaneous approach, and introduction of serum, toxoid, or vaccine into the pericardial cavity might use a percutaneous or open approach, illustrated by codes like 3E0Y3HZ. This vast coding range allows precise documentation of the type of substance, anatomical site, and technique used, ensuring detailed procedural records for therapies such as chemotherapy agents, vaccines, anesthetics, or diagnostic substances within ICD-10-PCS Introduction operation codes.

List of ICD-10-PCS codes used to specify 3E0 - Introduction (putting in or on a therapeutic, diagnostic, nutritional, physiological or prophylactic substance except blood or blood products). There are a total of 1062 procedure codes in this section.

• 3E0 - Administration, Physiological Systems and Anatomical Regions, Introduction

• 3E00X05 - Introduction of Other Antineoplastic into Skin and Mucous Membranes, External Approach

• 3E00X0M - Introduction of Antineoplastic, Monoclonal Antibody, into Skin and Mucous Membranes, External Approach

• 3E00X28 - Introduction of Oxazolidinones into Skin and Mucous Membranes, External Approach

• 3E00X29 - Introduction of Other Anti-infective into Skin and Mucous Membranes, External Approach

• 3E00X3Z - Introduction of Anti-inflammatory into Skin and Mucous Membranes, External Approach

• 3E00X4Z - Introduction of Serum, Toxoid and Vaccine into Skin and Mucous Membranes, External Approach

• 3E00XBZ - Introduction of Anesthetic Agent into Skin and Mucous Membranes, External Approach

• 3E00XGC - Introduction of Other Therapeutic Substance into Skin and Mucous Membranes, External Approach

• 3E00XKZ - Introduction of Other Diagnostic Substance into Skin and Mucous Membranes, External Approach

• 3E00XMZ - Introduction of Pigment into Skin and Mucous Membranes, External Approach

• 3E00XNZ - Introduction of Analgesics, Hypnotics, Sedatives into Skin and Mucous Membranes, External Approach

• 3E00XTZ - Introduction of Destructive Agent into Skin and Mucous Membranes, External Approach

• 3E0102A - Introduction of Anti-Infective Envelope into Subcutaneous Tissue, Open Approach

• 3E01305 - Introduction of Other Antineoplastic into Subcutaneous Tissue, Percutaneous Approach

• 3E0130M - Introduction of Antineoplastic, Monoclonal Antibody, into Subcutaneous Tissue, Percutaneous Approach

• 3E01328 - Introduction of Oxazolidinones into Subcutaneous Tissue, Percutaneous Approach

• 3E01329 - Introduction of Other Anti-infective into Subcutaneous Tissue, Percutaneous Approach

• 3E0132A - Introduction of Anti-Infective Envelope into Subcutaneous Tissue, Percutaneous Approach

• 3E0133Z - Introduction of Anti-inflammatory into Subcutaneous Tissue, Percutaneous Approach

• 3E01340 - Introduction of Influenza Vaccine into Subcutaneous Tissue, Percutaneous Approach

• 3E0134Z - Introduction of Serum, Toxoid and Vaccine into Subcutaneous Tissue, Percutaneous Approach

• 3E0136Z - Introduction of Nutritional Substance into Subcutaneous Tissue, Percutaneous Approach

• 3E0137Z - Introduction of Electrolytic and Water Balance Substance into Subcutaneous Tissue, Percutaneous Approach

• 3E013BZ - Introduction of Anesthetic Agent into Subcutaneous Tissue, Percutaneous Approach

• 3E013GC - Introduction of Other Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach

• 3E013HZ - Introduction of Radioactive Substance into Subcutaneous Tissue, Percutaneous Approach

• 3E013KZ - Introduction of Other Diagnostic Substance into Subcutaneous Tissue, Percutaneous Approach

• 3E013NZ - Introduction of Analgesics, Hypnotics, Sedatives into Subcutaneous Tissue, Percutaneous Approach

• 3E013TZ - Introduction of Destructive Agent into Subcutaneous Tissue, Percutaneous Approach

• 3E013VG - Introduction of Insulin into Subcutaneous Tissue, Percutaneous Approach

• 3E013VJ - Introduction of Other Hormone into Subcutaneous Tissue, Percutaneous Approach

• 3E02305 - Introduction of Other Antineoplastic into Muscle, Percutaneous Approach

• 3E0230M - Introduction of Antineoplastic, Monoclonal Antibody, into Muscle, Percutaneous Approach

• 3E02328 - Introduction of Oxazolidinones into Muscle, Percutaneous Approach

• 3E02329 - Introduction of Other Anti-infective into Muscle, Percutaneous Approach

• 3E0233Z - Introduction of Anti-inflammatory into Muscle, Percutaneous Approach

• 3E02340 - Introduction of Influenza Vaccine into Muscle, Percutaneous Approach

• 3E0234Z - Introduction of Serum, Toxoid and Vaccine into Muscle, Percutaneous Approach

• 3E0236Z - Introduction of Nutritional Substance into Muscle, Percutaneous Approach

• 3E0237Z - Introduction of Electrolytic and Water Balance Substance into Muscle, Percutaneous Approach

• 3E023BZ - Introduction of Anesthetic Agent into Muscle, Percutaneous Approach

• 3E023GC - Introduction of Other Therapeutic Substance into Muscle, Percutaneous Approach

• 3E023HZ - Introduction of Radioactive Substance into Muscle, Percutaneous Approach

• 3E023KZ - Introduction of Other Diagnostic Substance into Muscle, Percutaneous Approach

• 3E023NZ - Introduction of Analgesics, Hypnotics, Sedatives into Muscle, Percutaneous Approach

• 3E023TZ - Introduction of Destructive Agent into Muscle, Percutaneous Approach

• 3E03002 - Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach

• 3E03003 - Introduction of Low-dose Interleukin-2 into Peripheral Vein, Open Approach

• 3E03005 - Introduction of Other Antineoplastic into Peripheral Vein, Open Approach

• 3E0300M - Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Open Approach

• 3E0300P - Introduction of Clofarabine into Peripheral Vein, Open Approach

• 3E03016 - Introduction of Recombinant Human-activated Protein C into Peripheral Vein, Open

• 3E03017 - Introduction of Other Thrombolytic into Peripheral Vein, Open Approach

• 3E03028 - Introduction of Oxazolidinones into Peripheral Vein, Open Approach

• 3E03029 - Introduction of Other Anti-infective into Peripheral Vein, Open Approach

• 3E0303Z - Introduction of Anti-inflammatory into Peripheral Vein, Open Approach

• 3E0304Z - Introduction of Serum, Toxoid and Vaccine into Peripheral Vein, Open Approach

• 3E0306Z - Introduction of Nutritional Substance into Peripheral Vein, Open Approach

• 3E0307Z - Introduction of Electrolytic and Water Balance Substance into Peripheral Vein, Open Approach

• 3E030FZ - Introduction of Intracirculatory Anesthetic into Peripheral Vein, Open Approach

• 3E030GC - Introduction of Other Therapeutic Substance into Peripheral Vein, Open Approach

• 3E030GN - Introduction of Blood Brain Barrier Disruption Substance into Peripheral Vein, Open Approach

• 3E030HZ - Introduction of Radioactive Substance into Peripheral Vein, Open Approach

• 3E030KZ - Introduction of Other Diagnostic Substance into Peripheral Vein, Open Approach

• 3E030NZ - Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Vein, Open Approach

• 3E030PZ - Introduction of Platelet Inhibitor into Peripheral Vein, Open Approach

• 3E030RZ - Introduction of Antiarrhythmic into Peripheral Vein, Open Approach

• 3E030TZ - Introduction of Destructive Agent into Peripheral Vein, Open Approach

• 3E030U0 - Introduction of Autologous Pancreatic Islet Cells into Peripheral Vein, Open Approach

• 3E030U1 - Introduction of Nonautologous Pancreatic Islet Cells into Peripheral Vein, Open Approach

• 3E030VG - Introduction of Insulin into Peripheral Vein, Open Approach

• 3E030VH - Introduction of Human B-type Natriuretic Peptide into Peripheral Vein, Open Approach

• 3E030VJ - Introduction of Other Hormone into Peripheral Vein, Open Approach

• 3E030WK - Introduction of Immunostimulator into Peripheral Vein, Open

• 3E030WL - Introduction of Immunosuppressive into Peripheral Vein, Open

• 3E030XZ - Introduction of Vasopressor into Peripheral Vein, Open Approach

• 3E03302 - Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach

• 3E03303 - Introduction of Low-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach

• 3E03305 - Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach

• 3E0330M - Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Percutaneous Approach

• 3E0330P - Introduction of Clofarabine into Peripheral Vein, Percutaneous Approach

• 3E03316 - Introduction of Recombinant Human-activated Protein C into Peripheral Vein, Percutaneous

• 3E03317 - Introduction of Other Thrombolytic into Peripheral Vein, Percutaneous Approach

• 3E03328 - Introduction of Oxazolidinones into Peripheral Vein, Percutaneous Approach

• 3E03329 - Introduction of Other Anti-infective into Peripheral Vein, Percutaneous Approach

• 3E0333Z - Introduction of Anti-inflammatory into Peripheral Vein, Percutaneous Approach

• 3E0334Z - Introduction of Serum, Toxoid and Vaccine into Peripheral Vein, Percutaneous Approach

• 3E0336Z - Introduction of Nutritional Substance into Peripheral Vein, Percutaneous Approach

• 3E0337Z - Introduction of Electrolytic and Water Balance Substance into Peripheral Vein, Percutaneous Approach

• 3E033FZ - Introduction of Intracirculatory Anesthetic into Peripheral Vein, Percutaneous Approach

• 3E033GC - Introduction of Other Therapeutic Substance into Peripheral Vein, Percutaneous Approach

• 3E033GN - Introduction of Blood Brain Barrier Disruption Substance into Peripheral Vein, Percutaneous Approach

• 3E033GQ - Introduction of Glucarpidase into Peripheral Vein, Percutaneous Approach

• 3E033GR - Introduction of Other Therapeutic Monoclonal Antibody into Peripheral Vein, Percutaneous Approach

• 3E033HZ - Introduction of Radioactive Substance into Peripheral Vein, Percutaneous Approach

• 3E033KZ - Introduction of Other Diagnostic Substance into Peripheral Vein, Percutaneous Approach

• 3E033NZ - Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Vein, Percutaneous Approach

• 3E033PZ - Introduction of Platelet Inhibitor into Peripheral Vein, Percutaneous Approach

• 3E033RZ - Introduction of Antiarrhythmic into Peripheral Vein, Percutaneous Approach

• 3E033TZ - Introduction of Destructive Agent into Peripheral Vein, Percutaneous Approach

• 3E033U0 - Introduction of Autologous Pancreatic Islet Cells into Peripheral Vein, Percutaneous Approach

• 3E033U1 - Introduction of Nonautologous Pancreatic Islet Cells into Peripheral Vein, Percutaneous Approach

• 3E033VG - Introduction of Insulin into Peripheral Vein, Percutaneous Approach

• 3E033VH - Introduction of Human B-type Natriuretic Peptide into Peripheral Vein, Percutaneous Approach

• 3E033VJ - Introduction of Other Hormone into Peripheral Vein, Percutaneous Approach

• 3E033WK - Introduction of Immunostimulator into Peripheral Vein, Percutaneous

• 3E033WL - Introduction of Immunosuppressive into Peripheral Vein, Percutaneous

• 3E033XZ - Introduction of Vasopressor into Peripheral Vein, Percutaneous Approach

• 3E04002 - Introduction of High-dose Interleukin-2 into Central Vein, Open Approach

• 3E04003 - Introduction of Low-dose Interleukin-2 into Central Vein, Open Approach

• 3E04005 - Introduction of Other Antineoplastic into Central Vein, Open Approach

• 3E0400M - Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Open Approach

• 3E0400P - Introduction of Clofarabine into Central Vein, Open Approach

• 3E04016 - Introduction of Recombinant Human-activated Protein C into Central Vein, Open

• 3E04017 - Introduction of Other Thrombolytic into Central Vein, Open Approach

• 3E04028 - Introduction of Oxazolidinones into Central Vein, Open Approach

• 3E04029 - Introduction of Other Anti-infective into Central Vein, Open Approach

• 3E0403Z - Introduction of Anti-inflammatory into Central Vein, Open Approach

• 3E0404Z - Introduction of Serum, Toxoid and Vaccine into Central Vein, Open Approach

• 3E0406Z - Introduction of Nutritional Substance into Central Vein, Open Approach

• 3E0407Z - Introduction of Electrolytic and Water Balance Substance into Central Vein, Open Approach

• 3E040FZ - Introduction of Intracirculatory Anesthetic into Central Vein, Open Approach

• 3E040GC - Introduction of Other Therapeutic Substance into Central Vein, Open Approach

• 3E040GN - Introduction of Blood Brain Barrier Disruption Substance into Central Vein, Open Approach

• 3E040HZ - Introduction of Radioactive Substance into Central Vein, Open Approach

• 3E040KZ - Introduction of Other Diagnostic Substance into Central Vein, Open Approach

• 3E040NZ - Introduction of Analgesics, Hypnotics, Sedatives into Central Vein, Open Approach

• 3E040PZ - Introduction of Platelet Inhibitor into Central Vein, Open Approach

• 3E040RZ - Introduction of Antiarrhythmic into Central Vein, Open Approach

• 3E040TZ - Introduction of Destructive Agent into Central Vein, Open Approach

• 3E040VG - Introduction of Insulin into Central Vein, Open Approach

• 3E040VH - Introduction of Human B-type Natriuretic Peptide into Central Vein, Open Approach

• 3E040VJ - Introduction of Other Hormone into Central Vein, Open Approach

• 3E040WK - Introduction of Immunostimulator into Central Vein, Open

• 3E040WL - Introduction of Immunosuppressive into Central Vein, Open

• 3E040XZ - Introduction of Vasopressor into Central Vein, Open Approach

• 3E04302 - Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach

• 3E04303 - Introduction of Low-dose Interleukin-2 into Central Vein, Percutaneous Approach

• 3E04305 - Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach

• 3E0430M - Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Percutaneous Approach

• 3E0430P - Introduction of Clofarabine into Central Vein, Percutaneous Approach

• 3E04316 - Introduction of Recombinant Human-activated Protein C into Central Vein, Percutaneous

• 3E04317 - Introduction of Other Thrombolytic into Central Vein, Percutaneous Approach

• 3E04328 - Introduction of Oxazolidinones into Central Vein, Percutaneous Approach

• 3E04329 - Introduction of Other Anti-infective into Central Vein, Percutaneous Approach

• 3E0433Z - Introduction of Anti-inflammatory into Central Vein, Percutaneous Approach

• 3E0434Z - Introduction of Serum, Toxoid and Vaccine into Central Vein, Percutaneous Approach

• 3E0436Z - Introduction of Nutritional Substance into Central Vein, Percutaneous Approach

• 3E0437Z - Introduction of Electrolytic and Water Balance Substance into Central Vein, Percutaneous Approach

• 3E043FZ - Introduction of Intracirculatory Anesthetic into Central Vein, Percutaneous Approach

• 3E043GC - Introduction of Other Therapeutic Substance into Central Vein, Percutaneous Approach

• 3E043GN - Introduction of Blood Brain Barrier Disruption Substance into Central Vein, Percutaneous Approach

• 3E043GQ - Introduction of Glucarpidase into Central Vein, Percutaneous Approach

• 3E043GR - Introduction of Other Therapeutic Monoclonal Antibody into Central Vein, Percutaneous Approach

• 3E043HZ - Introduction of Radioactive Substance into Central Vein, Percutaneous Approach

• 3E043KZ - Introduction of Other Diagnostic Substance into Central Vein, Percutaneous Approach

• 3E043NZ - Introduction of Analgesics, Hypnotics, Sedatives into Central Vein, Percutaneous Approach

• 3E043PZ - Introduction of Platelet Inhibitor into Central Vein, Percutaneous Approach

• 3E043RZ - Introduction of Antiarrhythmic into Central Vein, Percutaneous Approach

• 3E043TZ - Introduction of Destructive Agent into Central Vein, Percutaneous Approach

• 3E043VG - Introduction of Insulin into Central Vein, Percutaneous Approach

• 3E043VH - Introduction of Human B-type Natriuretic Peptide into Central Vein, Percutaneous Approach

• 3E043VJ - Introduction of Other Hormone into Central Vein, Percutaneous Approach

• 3E043WK - Introduction of Immunostimulator into Central Vein, Percutaneous

• 3E043WL - Introduction of Immunosuppressive into Central Vein, Percutaneous

• 3E043XZ - Introduction of Vasopressor into Central Vein, Percutaneous Approach

• 3E05002 - Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach

• 3E05003 - Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach

• 3E05005 - Introduction of Other Antineoplastic into Peripheral Artery, Open Approach

• 3E0500M - Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Open Approach

• 3E0500P - Introduction of Clofarabine into Peripheral Artery, Open Approach

• 3E05016 - Introduction of Recombinant Human-activated Protein C into Peripheral Artery, Open

• 3E05017 - Introduction of Other Thrombolytic into Peripheral Artery, Open Approach

• 3E05028 - Introduction of Oxazolidinones into Peripheral Artery, Open Approach

• 3E05029 - Introduction of Other Anti-infective into Peripheral Artery, Open Approach

• 3E0503Z - Introduction of Anti-inflammatory into Peripheral Artery, Open Approach

• 3E0504Z - Introduction of Serum, Toxoid and Vaccine into Peripheral Artery, Open Approach

• 3E0506Z - Introduction of Nutritional Substance into Peripheral Artery, Open Approach

• 3E0507Z - Introduction of Electrolytic and Water Balance Substance into Peripheral Artery, Open Approach

• 3E050FZ - Introduction of Intracirculatory Anesthetic into Peripheral Artery, Open Approach

• 3E050GC - Introduction of Other Therapeutic Substance into Peripheral Artery, Open Approach

• 3E050GN - Introduction of Blood Brain Barrier Disruption Substance into Peripheral Artery, Open Approach

• 3E050HZ - Introduction of Radioactive Substance into Peripheral Artery, Open Approach

• 3E050KZ - Introduction of Other Diagnostic Substance into Peripheral Artery, Open Approach

• 3E050NZ - Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Artery, Open Approach

• 3E050PZ - Introduction of Platelet Inhibitor into Peripheral Artery, Open Approach

• 3E050RZ - Introduction of Antiarrhythmic into Peripheral Artery, Open Approach

• 3E050TZ - Introduction of Destructive Agent into Peripheral Artery, Open Approach

• 3E050VG - Introduction of Insulin into Peripheral Artery, Open Approach

• 3E050VH - Introduction of Human B-type Natriuretic Peptide into Peripheral Artery, Open Approach

• 3E050VJ - Introduction of Other Hormone into Peripheral Artery, Open Approach

• 3E050WK - Introduction of Immunostimulator into Peripheral Artery, Open

• 3E050WL - Introduction of Immunosuppressive into Peripheral Artery, Open

• 3E050XZ - Introduction of Vasopressor into Peripheral Artery, Open Approach

• 3E05302 - Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach

• 3E05303 - Introduction of Low-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach

• 3E05305 - Introduction of Other Antineoplastic into Peripheral Artery, Percutaneous Approach

• 3E0530M - Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Percutaneous Approach

• 3E0530P - Introduction of Clofarabine into Peripheral Artery, Percutaneous Approach

• 3E05316 - Introduction of Recombinant Human-activated Protein C into Peripheral Artery, Percutaneous

• 3E05317 - Introduction of Other Thrombolytic into Peripheral Artery, Percutaneous Approach

• 3E05328 - Introduction of Oxazolidinones into Peripheral Artery, Percutaneous Approach

• 3E05329 - Introduction of Other Anti-infective into Peripheral Artery, Percutaneous Approach

• 3E0533Z - Introduction of Anti-inflammatory into Peripheral Artery, Percutaneous Approach

• 3E0534Z - Introduction of Serum, Toxoid and Vaccine into Peripheral Artery, Percutaneous Approach

• 3E0536Z - Introduction of Nutritional Substance into Peripheral Artery, Percutaneous Approach

• 3E0537Z - Introduction of Electrolytic and Water Balance Substance into Peripheral Artery, Percutaneous Approach

• 3E053FZ - Introduction of Intracirculatory Anesthetic into Peripheral Artery, Percutaneous Approach

• 3E053GC - Introduction of Other Therapeutic Substance into Peripheral Artery, Percutaneous Approach

• 3E053GN - Introduction of Blood Brain Barrier Disruption Substance into Peripheral Artery, Percutaneous Approach

• 3E053HZ - Introduction of Radioactive Substance into Peripheral Artery, Percutaneous Approach

• 3E053KZ - Introduction of Other Diagnostic Substance into Peripheral Artery, Percutaneous Approach

• 3E053NZ - Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Artery, Percutaneous Approach

• 3E053PZ - Introduction of Platelet Inhibitor into Peripheral Artery, Percutaneous Approach

• 3E053RZ - Introduction of Antiarrhythmic into Peripheral Artery, Percutaneous Approach

• 3E053TZ - Introduction of Destructive Agent into Peripheral Artery, Percutaneous Approach

• 3E053VG - Introduction of Insulin into Peripheral Artery, Percutaneous Approach

• 3E053VH - Introduction of Human B-type Natriuretic Peptide into Peripheral Artery, Percutaneous Approach

• 3E053VJ - Introduction of Other Hormone into Peripheral Artery, Percutaneous Approach

• 3E053WK - Introduction of Immunostimulator into Peripheral Artery, Percutaneous

• 3E053WL - Introduction of Immunosuppressive into Peripheral Artery, Percutaneous

• 3E053XZ - Introduction of Vasopressor into Peripheral Artery, Percutaneous Approach

• 3E06002 - Introduction of High-dose Interleukin-2 into Central Artery, Open Approach

• 3E06003 - Introduction of Low-dose Interleukin-2 into Central Artery, Open Approach

• 3E06005 - Introduction of Other Antineoplastic into Central Artery, Open Approach

• 3E0600M - Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Open Approach

• 3E0600P - Introduction of Clofarabine into Central Artery, Open Approach

• 3E06016 - Introduction of Recombinant Human-activated Protein C into Central Artery, Open

• 3E06017 - Introduction of Other Thrombolytic into Central Artery, Open Approach

• 3E06028 - Introduction of Oxazolidinones into Central Artery, Open Approach

• 3E06029 - Introduction of Other Anti-infective into Central Artery, Open Approach

• 3E0603Z - Introduction of Anti-inflammatory into Central Artery, Open Approach

• 3E0604Z - Introduction of Serum, Toxoid and Vaccine into Central Artery, Open Approach

• 3E0606Z - Introduction of Nutritional Substance into Central Artery, Open Approach

• 3E0607Z - Introduction of Electrolytic and Water Balance Substance into Central Artery, Open Approach

• 3E060FZ - Introduction of Intracirculatory Anesthetic into Central Artery, Open Approach

• 3E060GC - Introduction of Other Therapeutic Substance into Central Artery, Open Approach

• 3E060GN - Introduction of Blood Brain Barrier Disruption Substance into Central Artery, Open Approach

• 3E060HZ - Introduction of Radioactive Substance into Central Artery, Open Approach

• 3E060KZ - Introduction of Other Diagnostic Substance into Central Artery, Open Approach

• 3E060NZ - Introduction of Analgesics, Hypnotics, Sedatives into Central Artery, Open Approach

• 3E060PZ - Introduction of Platelet Inhibitor into Central Artery, Open Approach

• 3E060RZ - Introduction of Antiarrhythmic into Central Artery, Open Approach

• 3E060TZ - Introduction of Destructive Agent into Central Artery, Open Approach

• 3E060VG - Introduction of Insulin into Central Artery, Open Approach

• 3E060VH - Introduction of Human B-type Natriuretic Peptide into Central Artery, Open Approach

• 3E060VJ - Introduction of Other Hormone into Central Artery, Open Approach

• 3E060WK - Introduction of Immunostimulator into Central Artery, Open

• 3E060WL - Introduction of Immunosuppressive into Central Artery, Open

• 3E060XZ - Introduction of Vasopressor into Central Artery, Open Approach

• 3E06302 - Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach

• 3E06303 - Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach

• 3E06305 - Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach

• 3E0630M - Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Percutaneous Approach

• 3E0630P - Introduction of Clofarabine into Central Artery, Percutaneous Approach

• 3E06316 - Introduction of Recombinant Human-activated Protein C into Central Artery, Percutaneous

• 3E06317 - Introduction of Other Thrombolytic into Central Artery, Percutaneous Approach

• 3E06328 - Introduction of Oxazolidinones into Central Artery, Percutaneous Approach

• 3E06329 - Introduction of Other Anti-infective into Central Artery, Percutaneous Approach

• 3E0633Z - Introduction of Anti-inflammatory into Central Artery, Percutaneous Approach

• 3E0634Z - Introduction of Serum, Toxoid and Vaccine into Central Artery, Percutaneous Approach

• 3E0636Z - Introduction of Nutritional Substance into Central Artery, Percutaneous Approach

• 3E0637Z - Introduction of Electrolytic and Water Balance Substance into Central Artery, Percutaneous Approach

• 3E063FZ - Introduction of Intracirculatory Anesthetic into Central Artery, Percutaneous Approach

• 3E063GC - Introduction of Other Therapeutic Substance into Central Artery, Percutaneous Approach

• 3E063GN - Introduction of Blood Brain Barrier Disruption Substance into Central Artery, Percutaneous Approach

• 3E063HZ - Introduction of Radioactive Substance into Central Artery, Percutaneous Approach

• 3E063KZ - Introduction of Other Diagnostic Substance into Central Artery, Percutaneous Approach

• 3E063NZ - Introduction of Analgesics, Hypnotics, Sedatives into Central Artery, Percutaneous Approach

• 3E063PZ - Introduction of Platelet Inhibitor into Central Artery, Percutaneous Approach

• 3E063RZ - Introduction of Antiarrhythmic into Central Artery, Percutaneous Approach

• 3E063TZ - Introduction of Destructive Agent into Central Artery, Percutaneous Approach

• 3E063VG - Introduction of Insulin into Central Artery, Percutaneous Approach

• 3E063VH - Introduction of Human B-type Natriuretic Peptide into Central Artery, Percutaneous Approach

• 3E063VJ - Introduction of Other Hormone into Central Artery, Percutaneous Approach

• 3E063WK - Introduction of Immunostimulator into Central Artery, Percutaneous

• 3E063WL - Introduction of Immunosuppressive into Central Artery, Percutaneous

• 3E063XZ - Introduction of Vasopressor into Central Artery, Percutaneous Approach

• 3E07016 - Introduction of Recombinant Human-activated Protein C into Coronary Artery, Open

• 3E07017 - Introduction of Other Thrombolytic into Coronary Artery, Open Approach

• 3E070GC - Introduction of Other Therapeutic Substance into Coronary Artery, Open Approach

• 3E070KZ - Introduction of Other Diagnostic Substance into Coronary Artery, Open Approach

• 3E070PZ - Introduction of Platelet Inhibitor into Coronary Artery, Open Approach

• 3E07316 - Introduction of Recombinant Human-activated Protein C into Coronary Artery, Percutaneous

• 3E07317 - Introduction of Other Thrombolytic into Coronary Artery, Percutaneous Approach

• 3E073GC - Introduction of Other Therapeutic Substance into Coronary Artery, Percutaneous Approach

• 3E073KZ - Introduction of Other Diagnostic Substance into Coronary Artery, Percutaneous Approach

• 3E073PZ - Introduction of Platelet Inhibitor into Coronary Artery, Percutaneous Approach

• 3E074GC - Introduction of Other Therapeutic Substance into Coronary Artery, Percutaneous Endoscopic Approach

• 3E08016 - Introduction of Recombinant Human-activated Protein C into Heart, Open

• 3E08017 - Introduction of Other Thrombolytic into Heart, Open Approach

• 3E080GC - Introduction of Other Therapeutic Substance into Heart, Open Approach

• 3E080KZ - Introduction of Other Diagnostic Substance into Heart, Open Approach

• 3E080PZ - Introduction of Platelet Inhibitor into Heart, Open Approach

• 3E08316 - Introduction of Recombinant Human-activated Protein C into Heart, Percutaneous

• 3E08317 - Introduction of Other Thrombolytic into Heart, Percutaneous Approach

• 3E083GC - Introduction of Other Therapeutic Substance into Heart, Percutaneous Approach

• 3E083KZ - Introduction of Other Diagnostic Substance into Heart, Percutaneous Approach

• 3E083PZ - Introduction of Platelet Inhibitor into Heart, Percutaneous Approach

• 3E084GC - Introduction of Other Therapeutic Substance into Heart, Percutaneous Endoscopic Approach

• 3E09305 - Introduction of Other Antineoplastic into Nose, Percutaneous Approach

• 3E0930M - Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Percutaneous Approach

• 3E09328 - Introduction of Oxazolidinones into Nose, Percutaneous Approach

• 3E09329 - Introduction of Other Anti-infective into Nose, Percutaneous Approach

• 3E0933Z - Introduction of Anti-inflammatory into Nose, Percutaneous Approach

• 3E0934Z - Introduction of Serum, Toxoid and Vaccine into Nose, Percutaneous Approach

• 3E093BZ - Introduction of Anesthetic Agent into Nose, Percutaneous Approach

• 3E093GC - Introduction of Other Therapeutic Substance into Nose, Percutaneous Approach

• 3E093HZ - Introduction of Radioactive Substance into Nose, Percutaneous Approach

• 3E093KZ - Introduction of Other Diagnostic Substance into Nose, Percutaneous Approach

• 3E093NZ - Introduction of Analgesics, Hypnotics, Sedatives into Nose, Percutaneous Approach

• 3E093TZ - Introduction of Destructive Agent into Nose, Percutaneous Approach

• 3E09705 - Introduction of Other Antineoplastic into Nose, Via Natural or Artificial Opening

• 3E0970M - Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Via Natural or Artificial Opening

• 3E09728 - Introduction of Oxazolidinones into Nose, Via Natural or Artificial Opening

• 3E09729 - Introduction of Other Anti-infective into Nose, Via Natural or Artificial Opening

• 3E0973Z - Introduction of Anti-inflammatory into Nose, Via Natural or Artificial Opening

• 3E0974Z - Introduction of Serum, Toxoid and Vaccine into Nose, Via Natural or Artificial Opening

• 3E097BZ - Introduction of Anesthetic Agent into Nose, Via Natural or Artificial Opening

• 3E097GC - Introduction of Other Therapeutic Substance into Nose, Via Natural or Artificial Opening

• 3E097HZ - Introduction of Radioactive Substance into Nose, Via Natural or Artificial Opening

• 3E097KZ - Introduction of Other Diagnostic Substance into Nose, Via Natural or Artificial Opening

• 3E097NZ - Introduction of Analgesics, Hypnotics, Sedatives into Nose, Via Natural or Artificial Opening

• 3E097TZ - Introduction of Destructive Agent into Nose, Via Natural or Artificial Opening

• 3E09X05 - Introduction of Other Antineoplastic into Nose, External Approach

• 3E09X0M - Introduction of Antineoplastic, Monoclonal Antibody, into Nose, External Approach

• 3E09X28 - Introduction of Oxazolidinones into Nose, External Approach

• 3E09X29 - Introduction of Other Anti-infective into Nose, External Approach

• 3E09X3Z - Introduction of Anti-inflammatory into Nose, External Approach

• 3E09X4Z - Introduction of Serum, Toxoid and Vaccine into Nose, External Approach

• 3E09XBZ - Introduction of Anesthetic Agent into Nose, External Approach

• 3E09XGC - Introduction of Other Therapeutic Substance into Nose, External Approach

• 3E09XHZ - Introduction of Radioactive Substance into Nose, External Approach

• 3E09XKZ - Introduction of Other Diagnostic Substance into Nose, External Approach

• 3E09XNZ - Introduction of Analgesics, Hypnotics, Sedatives into Nose, External Approach

• 3E09XTZ - Introduction of Destructive Agent into Nose, External Approach

• 3E0A305 - Introduction of Other Antineoplastic into Bone Marrow, Percutaneous Approach

• 3E0A30M - Introduction of Antineoplastic, Monoclonal Antibody, into Bone Marrow, Percutaneous Approach

• 3E0A3GC - Introduction of Other Therapeutic Substance into Bone Marrow, Percutaneous Approach

• 3E0B304 - Introduction of Liquid Brachytherapy Radioisotope into Ear, Percutaneous Approach

• 3E0B305 - Introduction of Other Antineoplastic into Ear, Percutaneous Approach

• 3E0B30M - Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Percutaneous Approach

• 3E0B328 - Introduction of Oxazolidinones into Ear, Percutaneous Approach

• 3E0B329 - Introduction of Other Anti-infective into Ear, Percutaneous Approach

• 3E0B33Z - Introduction of Anti-inflammatory into Ear, Percutaneous Approach

• 3E0B3BZ - Introduction of Anesthetic Agent into Ear, Percutaneous Approach

• 3E0B3GC - Introduction of Other Therapeutic Substance into Ear, Percutaneous Approach

• 3E0B3HZ - Introduction of Radioactive Substance into Ear, Percutaneous Approach

• 3E0B3KZ - Introduction of Other Diagnostic Substance into Ear, Percutaneous Approach

• 3E0B3NZ - Introduction of Analgesics, Hypnotics, Sedatives into Ear, Percutaneous Approach

• 3E0B3TZ - Introduction of Destructive Agent into Ear, Percutaneous Approach

• 3E0B704 - Introduction of Liquid Brachytherapy Radioisotope into Ear, Via Natural or Artificial Opening

• 3E0B705 - Introduction of Other Antineoplastic into Ear, Via Natural or Artificial Opening

• 3E0B70M - Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Via Natural or Artificial Opening

• 3E0B728 - Introduction of Oxazolidinones into Ear, Via Natural or Artificial Opening

• 3E0B729 - Introduction of Other Anti-infective into Ear, Via Natural or Artificial Opening

• 3E0B73Z - Introduction of Anti-inflammatory into Ear, Via Natural or Artificial Opening

• 3E0B7BZ - Introduction of Anesthetic Agent into Ear, Via Natural or Artificial Opening

• 3E0B7GC - Introduction of Other Therapeutic Substance into Ear, Via Natural or Artificial Opening

• 3E0B7HZ - Introduction of Radioactive Substance into Ear, Via Natural or Artificial Opening

• 3E0B7KZ - Introduction of Other Diagnostic Substance into Ear, Via Natural or Artificial Opening

• 3E0B7NZ - Introduction of Analgesics, Hypnotics, Sedatives into Ear, Via Natural or Artificial Opening

• 3E0B7TZ - Introduction of Destructive Agent into Ear, Via Natural or Artificial Opening

• 3E0BX04 - Introduction of Liquid Brachytherapy Radioisotope into Ear, External Approach

• 3E0BX05 - Introduction of Other Antineoplastic into Ear, External Approach

• 3E0BX0M - Introduction of Antineoplastic, Monoclonal Antibody, into Ear, External Approach

• 3E0BX28 - Introduction of Oxazolidinones into Ear, External Approach

• 3E0BX29 - Introduction of Other Anti-infective into Ear, External Approach

• 3E0BX3Z - Introduction of Anti-inflammatory into Ear, External Approach

• 3E0BXBZ - Introduction of Anesthetic Agent into Ear, External Approach

• 3E0BXGC - Introduction of Other Therapeutic Substance into Ear, External Approach

• 3E0BXHZ - Introduction of Radioactive Substance into Ear, External Approach

• 3E0BXKZ - Introduction of Other Diagnostic Substance into Ear, External Approach

• 3E0BXNZ - Introduction of Analgesics, Hypnotics, Sedatives into Ear, External Approach

• 3E0BXTZ - Introduction of Destructive Agent into Ear, External Approach

• 3E0C304 - Introduction of Liquid Brachytherapy Radioisotope into Eye, Percutaneous Approach

• 3E0C305 - Introduction of Other Antineoplastic into Eye, Percutaneous Approach

• 3E0C30M - Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Percutaneous Approach

• 3E0C328 - Introduction of Oxazolidinones into Eye, Percutaneous Approach

• 3E0C329 - Introduction of Other Anti-infective into Eye, Percutaneous Approach

• 3E0C33Z - Introduction of Anti-inflammatory into Eye, Percutaneous Approach

• 3E0C3BZ - Introduction of Anesthetic Agent into Eye, Percutaneous Approach

• 3E0C3GC - Introduction of Other Therapeutic Substance into Eye, Percutaneous Approach

• 3E0C3HZ - Introduction of Radioactive Substance into Eye, Percutaneous Approach

• 3E0C3KZ - Introduction of Other Diagnostic Substance into Eye, Percutaneous Approach

• 3E0C3MZ - Introduction of Pigment into Eye, Percutaneous Approach

• 3E0C3NZ - Introduction of Analgesics, Hypnotics, Sedatives into Eye, Percutaneous Approach

• 3E0C3SF - Introduction of Other Gas into Eye, Percutaneous Approach

• 3E0C3TZ - Introduction of Destructive Agent into Eye, Percutaneous Approach

• 3E0C704 - Introduction of Liquid Brachytherapy Radioisotope into Eye, Via Natural or Artificial Opening

• 3E0C705 - Introduction of Other Antineoplastic into Eye, Via Natural or Artificial Opening

• 3E0C70M - Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Via Natural or Artificial Opening

• 3E0C728 - Introduction of Oxazolidinones into Eye, Via Natural or Artificial Opening

• 3E0C729 - Introduction of Other Anti-infective into Eye, Via Natural or Artificial Opening

• 3E0C73Z - Introduction of Anti-inflammatory into Eye, Via Natural or Artificial Opening

• 3E0C7BZ - Introduction of Anesthetic Agent into Eye, Via Natural or Artificial Opening

• 3E0C7GC - Introduction of Other Therapeutic Substance into Eye, Via Natural or Artificial Opening

• 3E0C7HZ - Introduction of Radioactive Substance into Eye, Via Natural or Artificial Opening

• 3E0C7KZ - Introduction of Other Diagnostic Substance into Eye, Via Natural or Artificial Opening

• 3E0C7MZ - Introduction of Pigment into Eye, Via Natural or Artificial Opening

• 3E0C7NZ - Introduction of Analgesics, Hypnotics, Sedatives into Eye, Via Natural or Artificial Opening

• 3E0C7SF - Introduction of Other Gas into Eye, Via Natural or Artificial Opening

• 3E0C7TZ - Introduction of Destructive Agent into Eye, Via Natural or Artificial Opening

• 3E0CX04 - Introduction of Liquid Brachytherapy Radioisotope into Eye, External Approach

• 3E0CX05 - Introduction of Other Antineoplastic into Eye, External Approach

• 3E0CX0M - Introduction of Antineoplastic, Monoclonal Antibody, into Eye, External Approach

• 3E0CX28 - Introduction of Oxazolidinones into Eye, External Approach

• 3E0CX29 - Introduction of Other Anti-infective into Eye, External Approach

• 3E0CX3Z - Introduction of Anti-inflammatory into Eye, External Approach

• 3E0CXBZ - Introduction of Anesthetic Agent into Eye, External Approach

• 3E0CXGC - Introduction of Other Therapeutic Substance into Eye, External Approach

• 3E0CXHZ - Introduction of Radioactive Substance into Eye, External Approach

• 3E0CXKZ - Introduction of Other Diagnostic Substance into Eye, External Approach

• 3E0CXMZ - Introduction of Pigment into Eye, External Approach

• 3E0CXNZ - Introduction of Analgesics, Hypnotics, Sedatives into Eye, External Approach

• 3E0CXSF - Introduction of Other Gas into Eye, External Approach

• 3E0CXTZ - Introduction of Destructive Agent into Eye, External Approach

• 3E0D304 - Introduction of Liquid Brachytherapy Radioisotope into Mouth and Pharynx, Percutaneous Approach

• 3E0D305 - Introduction of Other Antineoplastic into Mouth and Pharynx, Percutaneous Approach

• 3E0D30M - Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Percutaneous Approach

• 3E0D328 - Introduction of Oxazolidinones into Mouth and Pharynx, Percutaneous Approach

• 3E0D329 - Introduction of Other Anti-infective into Mouth and Pharynx, Percutaneous Approach

• 3E0D33Z - Introduction of Anti-inflammatory into Mouth and Pharynx, Percutaneous Approach

• 3E0D34Z - Introduction of Serum, Toxoid and Vaccine into Mouth and Pharynx, Percutaneous Approach

• 3E0D36Z - Introduction of Nutritional Substance into Mouth and Pharynx, Percutaneous Approach

• 3E0D37Z - Introduction of Electrolytic and Water Balance Substance into Mouth and Pharynx, Percutaneous Approach

• 3E0D3BZ - Introduction of Anesthetic Agent into Mouth and Pharynx, Percutaneous Approach

• 3E0D3GC - Introduction of Other Therapeutic Substance into Mouth and Pharynx, Percutaneous Approach

• 3E0D3HZ - Introduction of Radioactive Substance into Mouth and Pharynx, Percutaneous Approach

• 3E0D3KZ - Introduction of Other Diagnostic Substance into Mouth and Pharynx, Percutaneous Approach

• 3E0D3NZ - Introduction of Analgesics, Hypnotics, Sedatives into Mouth and Pharynx, Percutaneous Approach

• 3E0D3RZ - Introduction of Antiarrhythmic into Mouth and Pharynx, Percutaneous Approach

• 3E0D3TZ - Introduction of Destructive Agent into Mouth and Pharynx, Percutaneous Approach

• 3E0D704 - Introduction of Liquid Brachytherapy Radioisotope into Mouth and Pharynx, Via Natural or Artificial Opening

• 3E0D705 - Introduction of Other Antineoplastic into Mouth and Pharynx, Via Natural or Artificial Opening

• 3E0D70M - Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Via Natural or Artificial Opening

• 3E0D728 - Introduction of Oxazolidinones into Mouth and Pharynx, Via Natural or Artificial Opening

• 3E0D729 - Introduction of Other Anti-infective into Mouth and Pharynx, Via Natural or Artificial Opening

• 3E0D73Z - Introduction of Anti-inflammatory into Mouth and Pharynx, Via Natural or Artificial Opening

• 3E0D74Z - Introduction of Serum, Toxoid and Vaccine into Mouth and Pharynx, Via Natural or Artificial Opening

• 3E0D76Z - Introduction of Nutritional Substance into Mouth and Pharynx, Via Natural or Artificial Opening

• 3E0D77Z - Introduction of Electrolytic and Water Balance Substance into Mouth and Pharynx, Via Natural or Artificial Opening

• 3E0D7BZ - Introduction of Anesthetic Agent into Mouth and Pharynx, Via Natural or Artificial Opening

• 3E0D7GC - Introduction of Other Therapeutic Substance into Mouth and Pharynx, Via Natural or Artificial Opening

• 3E0D7HZ - Introduction of Radioactive Substance into Mouth and Pharynx, Via Natural or Artificial Opening

• 3E0D7KZ - Introduction of Other Diagnostic Substance into Mouth and Pharynx, Via Natural or Artificial Opening

• 3E0D7NZ - Introduction of Analgesics, Hypnotics, Sedatives into Mouth and Pharynx, Via Natural or Artificial Opening

• 3E0D7RZ - Introduction of Antiarrhythmic into Mouth and Pharynx, Via Natural or Artificial Opening

• 3E0D7TZ - Introduction of Destructive Agent into Mouth and Pharynx, Via Natural or Artificial Opening

• 3E0DX04 - Introduction of Liquid Brachytherapy Radioisotope into Mouth and Pharynx, External Approach

• 3E0DX05 - Introduction of Other Antineoplastic into Mouth and Pharynx, External Approach

• 3E0DX0M - Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, External Approach

• 3E0DX28 - Introduction of Oxazolidinones into Mouth and Pharynx, External Approach

• 3E0DX29 - Introduction of Other Anti-infective into Mouth and Pharynx, External Approach

• 3E0DX3Z - Introduction of Anti-inflammatory into Mouth and Pharynx, External Approach

• 3E0DX4Z - Introduction of Serum, Toxoid and Vaccine into Mouth and Pharynx, External Approach

• 3E0DX6Z - Introduction of Nutritional Substance into Mouth and Pharynx, External Approach

• 3E0DX7Z - Introduction of Electrolytic and Water Balance Substance into Mouth and Pharynx, External Approach

• 3E0DXBZ - Introduction of Anesthetic Agent into Mouth and Pharynx, External Approach

• 3E0DXGC - Introduction of Other Therapeutic Substance into Mouth and Pharynx, External Approach

• 3E0DXHZ - Introduction of Radioactive Substance into Mouth and Pharynx, External Approach

• 3E0DXKZ - Introduction of Other Diagnostic Substance into Mouth and Pharynx, External Approach

• 3E0DXNZ - Introduction of Analgesics, Hypnotics, Sedatives into Mouth and Pharynx, External Approach

• 3E0DXRZ - Introduction of Antiarrhythmic into Mouth and Pharynx, External Approach

• 3E0DXTZ - Introduction of Destructive Agent into Mouth and Pharynx, External Approach

• 3E0E304 - Introduction of Liquid Brachytherapy Radioisotope into Products of Conception, Percutaneous Approach

• 3E0E305 - Introduction of Other Antineoplastic into Products of Conception, Percutaneous Approach

• 3E0E30M - Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Percutaneous Approach

• 3E0E328 - Introduction of Oxazolidinones into Products of Conception, Percutaneous Approach

• 3E0E329 - Introduction of Other Anti-infective into Products of Conception, Percutaneous Approach

• 3E0E33Z - Introduction of Anti-inflammatory into Products of Conception, Percutaneous Approach

• 3E0E36Z - Introduction of Nutritional Substance into Products of Conception, Percutaneous Approach

• 3E0E37Z - Introduction of Electrolytic and Water Balance Substance into Products of Conception, Percutaneous Approach

• 3E0E3BZ - Introduction of Anesthetic Agent into Products of Conception, Percutaneous Approach

• 3E0E3GC - Introduction of Other Therapeutic Substance into Products of Conception, Percutaneous Approach

• 3E0E3HZ - Introduction of Radioactive Substance into Products of Conception, Percutaneous Approach

• 3E0E3KZ - Introduction of Other Diagnostic Substance into Products of Conception, Percutaneous Approach

• 3E0E3NZ - Introduction of Analgesics, Hypnotics, Sedatives into Products of Conception, Percutaneous Approach

• 3E0E3SF - Introduction of Other Gas into Products of Conception, Percutaneous Approach

• 3E0E3TZ - Introduction of Destructive Agent into Products of Conception, Percutaneous Approach

• 3E0E4GC - Introduction of Other Therapeutic Substance into Products of Conception, Percutaneous Endoscopic Approach

• 3E0E704 - Introduction of Liquid Brachytherapy Radioisotope into Products of Conception, Via Natural or Artificial Opening

• 3E0E705 - Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening

• 3E0E70M - Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening

• 3E0E728 - Introduction of Oxazolidinones into Products of Conception, Via Natural or Artificial Opening

• 3E0E729 - Introduction of Other Anti-infective into Products of Conception, Via Natural or Artificial Opening

• 3E0E73Z - Introduction of Anti-inflammatory into Products of Conception, Via Natural or Artificial Opening

• 3E0E76Z - Introduction of Nutritional Substance into Products of Conception, Via Natural or Artificial Opening

• 3E0E77Z - Introduction of Electrolytic and Water Balance Substance into Products of Conception, Via Natural or Artificial Opening

• 3E0E7BZ - Introduction of Anesthetic Agent into Products of Conception, Via Natural or Artificial Opening

• 3E0E7GC - Introduction of Other Therapeutic Substance into Products of Conception, Via Natural or Artificial Opening

• 3E0E7HZ - Introduction of Radioactive Substance into Products of Conception, Via Natural or Artificial Opening

• 3E0E7KZ - Introduction of Other Diagnostic Substance into Products of Conception, Via Natural or Artificial Opening

• 3E0E7NZ - Introduction of Analgesics, Hypnotics, Sedatives into Products of Conception, Via Natural or Artificial Opening

• 3E0E7SF - Introduction of Other Gas into Products of Conception, Via Natural or Artificial Opening

• 3E0E7TZ - Introduction of Destructive Agent into Products of Conception, Via Natural or Artificial Opening

• 3E0E804 - Introduction of Liquid Brachytherapy Radioisotope into Products of Conception, Via Natural or Artificial Opening Endosco...

• 3E0E805 - Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening Endoscopic

• 3E0E80M - Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening Endo...

• 3E0E828 - Introduction of Oxazolidinones into Products of Conception, Via Natural or Artificial Opening Endoscopic

• 3E0E829 - Introduction of Other Anti-infective into Products of Conception, Via Natural or Artificial Opening Endoscopic

• 3E0E83Z - Introduction of Anti-inflammatory into Products of Conception, Via Natural or Artificial Opening Endoscopic

• 3E0E86Z - Introduction of Nutritional Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic

• 3E0E87Z - Introduction of Electrolytic and Water Balance Substance into Products of Conception, Via Natural or Artificial Opening ...

• 3E0E8BZ - Introduction of Anesthetic Agent into Products of Conception, Via Natural or Artificial Opening Endoscopic

• 3E0E8GC - Introduction of Other Therapeutic Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic

• 3E0E8HZ - Introduction of Radioactive Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic

• 3E0E8KZ - Introduction of Other Diagnostic Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic

• 3E0E8NZ - Introduction of Analgesics, Hypnotics, Sedatives into Products of Conception, Via Natural or Artificial Opening Endoscop...

• 3E0E8SF - Introduction of Other Gas into Products of Conception, Via Natural or Artificial Opening Endoscopic

• 3E0E8TZ - Introduction of Destructive Agent into Products of Conception, Via Natural or Artificial Opening Endoscopic

• 3E0F304 - Introduction of Liquid Brachytherapy Radioisotope into Respiratory Tract, Percutaneous Approach

• 3E0F305 - Introduction of Other Antineoplastic into Respiratory Tract, Percutaneous Approach

• 3E0F30M - Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Percutaneous Approach

• 3E0F328 - Introduction of Oxazolidinones into Respiratory Tract, Percutaneous Approach

• 3E0F329 - Introduction of Other Anti-infective into Respiratory Tract, Percutaneous Approach

• 3E0F33Z - Introduction of Anti-inflammatory into Respiratory Tract, Percutaneous Approach

• 3E0F36Z - Introduction of Nutritional Substance into Respiratory Tract, Percutaneous Approach

• 3E0F37Z - Introduction of Electrolytic and Water Balance Substance into Respiratory Tract, Percutaneous Approach

• 3E0F3BZ - Introduction of Anesthetic Agent into Respiratory Tract, Percutaneous Approach

• 3E0F3GC - Introduction of Other Therapeutic Substance into Respiratory Tract, Percutaneous Approach

• 3E0F3HZ - Introduction of Radioactive Substance into Respiratory Tract, Percutaneous Approach

• 3E0F3KZ - Introduction of Other Diagnostic Substance into Respiratory Tract, Percutaneous Approach

• 3E0F3NZ - Introduction of Analgesics, Hypnotics, Sedatives into Respiratory Tract, Percutaneous Approach

• 3E0F3SD - Introduction of Nitric Oxide Gas into Respiratory Tract, Percutaneous Approach

• 3E0F3SF - Introduction of Other Gas into Respiratory Tract, Percutaneous Approach

• 3E0F3TZ - Introduction of Destructive Agent into Respiratory Tract, Percutaneous Approach

• 3E0F4GC - Introduction of Other Therapeutic Substance into Respiratory Tract, Percutaneous Endoscopic Approach

• 3E0F704 - Introduction of Liquid Brachytherapy Radioisotope into Respiratory Tract, Via Natural or Artificial Opening

• 3E0F705 - Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening

• 3E0F70M - Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening

• 3E0F728 - Introduction of Oxazolidinones into Respiratory Tract, Via Natural or Artificial Opening

• 3E0F729 - Introduction of Other Anti-infective into Respiratory Tract, Via Natural or Artificial Opening

• 3E0F73Z - Introduction of Anti-inflammatory into Respiratory Tract, Via Natural or Artificial Opening

• 3E0F76Z - Introduction of Nutritional Substance into Respiratory Tract, Via Natural or Artificial Opening

• 3E0F77Z - Introduction of Electrolytic and Water Balance Substance into Respiratory Tract, Via Natural or Artificial Opening

• 3E0F7BZ - Introduction of Anesthetic Agent into Respiratory Tract, Via Natural or Artificial Opening

• 3E0F7GC - Introduction of Other Therapeutic Substance into Respiratory Tract, Via Natural or Artificial Opening

• 3E0F7HZ - Introduction of Radioactive Substance into Respiratory Tract, Via Natural or Artificial Opening

• 3E0F7KZ - Introduction of Other Diagnostic Substance into Respiratory Tract, Via Natural or Artificial Opening

• 3E0F7NZ - Introduction of Analgesics, Hypnotics, Sedatives into Respiratory Tract, Via Natural or Artificial Opening

• 3E0F7SD - Introduction of Nitric Oxide Gas into Respiratory Tract, Via Natural or Artificial Opening

• 3E0F7SF - Introduction of Other Gas into Respiratory Tract, Via Natural or Artificial Opening

• 3E0F7TZ - Introduction of Destructive Agent into Respiratory Tract, Via Natural or Artificial Opening

• 3E0F804 - Introduction of Liquid Brachytherapy Radioisotope into Respiratory Tract, Via Natural or Artificial Opening Endoscopic

• 3E0F805 - Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening Endoscopic

• 3E0F80M - Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening Endoscopi...

• 3E0F828 - Introduction of Oxazolidinones into Respiratory Tract, Via Natural or Artificial Opening Endoscopic

• 3E0F829 - Introduction of Other Anti-infective into Respiratory Tract, Via Natural or Artificial Opening Endoscopic

• 3E0F83Z - Introduction of Anti-inflammatory into Respiratory Tract, Via Natural or Artificial Opening Endoscopic

• 3E0F86Z - Introduction of Nutritional Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic

• 3E0F87Z - Introduction of Electrolytic and Water Balance Substance into Respiratory Tract, Via Natural or Artificial Opening Endos...

• 3E0F8BZ - Introduction of Anesthetic Agent into Respiratory Tract, Via Natural or Artificial Opening Endoscopic

• 3E0F8GC - Introduction of Other Therapeutic Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic

• 3E0F8HZ - Introduction of Radioactive Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic

• 3E0F8KZ - Introduction of Other Diagnostic Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic

• 3E0F8NZ - Introduction of Analgesics, Hypnotics, Sedatives into Respiratory Tract, Via Natural or Artificial Opening Endoscopic

• 3E0F8SD - Introduction of Nitric Oxide Gas into Respiratory Tract, Via Natural or Artificial Opening Endoscopic

• 3E0F8SF - Introduction of Other Gas into Respiratory Tract, Via Natural or Artificial Opening Endoscopic

• 3E0F8TZ - Introduction of Destructive Agent into Respiratory Tract, Via Natural or Artificial Opening Endoscopic

• 3E0G304 - Introduction of Liquid Brachytherapy Radioisotope into Upper GI, Percutaneous Approach

• 3E0G305 - Introduction of Other Antineoplastic into Upper GI, Percutaneous Approach

• 3E0G30M - Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Percutaneous Approach

• 3E0G328 - Introduction of Oxazolidinones into Upper GI, Percutaneous Approach

• 3E0G329 - Introduction of Other Anti-infective into Upper GI, Percutaneous Approach

• 3E0G33Z - Introduction of Anti-inflammatory into Upper GI, Percutaneous Approach

• 3E0G36Z - Introduction of Nutritional Substance into Upper GI, Percutaneous Approach

• 3E0G37Z - Introduction of Electrolytic and Water Balance Substance into Upper GI, Percutaneous Approach

• 3E0G3BZ - Introduction of Anesthetic Agent into Upper GI, Percutaneous Approach

• 3E0G3GC - Introduction of Other Therapeutic Substance into Upper GI, Percutaneous Approach

• 3E0G3HZ - Introduction of Radioactive Substance into Upper GI, Percutaneous Approach

• 3E0G3KZ - Introduction of Other Diagnostic Substance into Upper GI, Percutaneous Approach

• 3E0G3NZ - Introduction of Analgesics, Hypnotics, Sedatives into Upper GI, Percutaneous Approach

• 3E0G3SF - Introduction of Other Gas into Upper GI, Percutaneous Approach

• 3E0G3TZ - Introduction of Destructive Agent into Upper GI, Percutaneous Approach

• 3E0G4GC - Introduction of Other Therapeutic Substance into Upper GI, Percutaneous Endoscopic Approach

• 3E0G704 - Introduction of Liquid Brachytherapy Radioisotope into Upper GI, Via Natural or Artificial Opening

• 3E0G705 - Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening

• 3E0G70M - Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening

• 3E0G728 - Introduction of Oxazolidinones into Upper GI, Via Natural or Artificial Opening

• 3E0G729 - Introduction of Other Anti-infective into Upper GI, Via Natural or Artificial Opening

• 3E0G73Z - Introduction of Anti-inflammatory into Upper GI, Via Natural or Artificial Opening

• 3E0G76Z - Introduction of Nutritional Substance into Upper GI, Via Natural or Artificial Opening

• 3E0G77Z - Introduction of Electrolytic and Water Balance Substance into Upper GI, Via Natural or Artificial Opening

• 3E0G7BZ - Introduction of Anesthetic Agent into Upper GI, Via Natural or Artificial Opening

• 3E0G7GC - Introduction of Other Therapeutic Substance into Upper GI, Via Natural or Artificial Opening

• 3E0G7HZ - Introduction of Radioactive Substance into Upper GI, Via Natural or Artificial Opening

• 3E0G7KZ - Introduction of Other Diagnostic Substance into Upper GI, Via Natural or Artificial Opening

• 3E0G7NZ - Introduction of Analgesics, Hypnotics, Sedatives into Upper GI, Via Natural or Artificial Opening

• 3E0G7SF - Introduction of Other Gas into Upper GI, Via Natural or Artificial Opening

• 3E0G7TZ - Introduction of Destructive Agent into Upper GI, Via Natural or Artificial Opening

• 3E0G804 - Introduction of Liquid Brachytherapy Radioisotope into Upper GI, Via Natural or Artificial Opening Endoscopic

• 3E0G805 - Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening Endoscopic

• 3E0G80M - Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening Endoscopic

• 3E0G828 - Introduction of Oxazolidinones into Upper GI, Via Natural or Artificial Opening Endoscopic

• 3E0G829 - Introduction of Other Anti-infective into Upper GI, Via Natural or Artificial Opening Endoscopic

• 3E0G83Z - Introduction of Anti-inflammatory into Upper GI, Via Natural or Artificial Opening Endoscopic

• 3E0G86Z - Introduction of Nutritional Substance into Upper GI, Via Natural or Artificial Opening Endoscopic

• 3E0G87Z - Introduction of Electrolytic and Water Balance Substance into Upper GI, Via Natural or Artificial Opening Endoscopic

• 3E0G8BZ - Introduction of Anesthetic Agent into Upper GI, Via Natural or Artificial Opening Endoscopic

• 3E0G8GC - Introduction of Other Therapeutic Substance into Upper GI, Via Natural or Artificial Opening Endoscopic

• 3E0G8HZ - Introduction of Radioactive Substance into Upper GI, Via Natural or Artificial Opening Endoscopic

• 3E0G8KZ - Introduction of Other Diagnostic Substance into Upper GI, Via Natural or Artificial Opening Endoscopic

• 3E0G8NZ - Introduction of Analgesics, Hypnotics, Sedatives into Upper GI, Via Natural or Artificial Opening Endoscopic

• 3E0G8SF - Introduction of Other Gas into Upper GI, Via Natural or Artificial Opening Endoscopic

• 3E0G8TZ - Introduction of Destructive Agent into Upper GI, Via Natural or Artificial Opening Endoscopic

• 3E0H304 - Introduction of Liquid Brachytherapy Radioisotope into Lower GI, Percutaneous Approach

• 3E0H305 - Introduction of Other Antineoplastic into Lower GI, Percutaneous Approach

• 3E0H30M - Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Percutaneous Approach

• 3E0H328 - Introduction of Oxazolidinones into Lower GI, Percutaneous Approach

• 3E0H329 - Introduction of Other Anti-infective into Lower GI, Percutaneous Approach

• 3E0H33Z - Introduction of Anti-inflammatory into Lower GI, Percutaneous Approach

• 3E0H36Z - Introduction of Nutritional Substance into Lower GI, Percutaneous Approach

• 3E0H37Z - Introduction of Electrolytic and Water Balance Substance into Lower GI, Percutaneous Approach

• 3E0H3BZ - Introduction of Anesthetic Agent into Lower GI, Percutaneous Approach

• 3E0H3GC - Introduction of Other Therapeutic Substance into Lower GI, Percutaneous Approach

• 3E0H3HZ - Introduction of Radioactive Substance into Lower GI, Percutaneous Approach

• 3E0H3KZ - Introduction of Other Diagnostic Substance into Lower GI, Percutaneous Approach

• 3E0H3NZ - Introduction of Analgesics, Hypnotics, Sedatives into Lower GI, Percutaneous Approach

• 3E0H3SF - Introduction of Other Gas into Lower GI, Percutaneous Approach

• 3E0H3TZ - Introduction of Destructive Agent into Lower GI, Percutaneous Approach

• 3E0H4GC - Introduction of Other Therapeutic Substance into Lower GI, Percutaneous Endoscopic Approach

• 3E0H704 - Introduction of Liquid Brachytherapy Radioisotope into Lower GI, Via Natural or Artificial Opening

• 3E0H705 - Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening

• 3E0H70M - Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening

• 3E0H728 - Introduction of Oxazolidinones into Lower GI, Via Natural or Artificial Opening

• 3E0H729 - Introduction of Other Anti-infective into Lower GI, Via Natural or Artificial Opening

• 3E0H73Z - Introduction of Anti-inflammatory into Lower GI, Via Natural or Artificial Opening

• 3E0H76Z - Introduction of Nutritional Substance into Lower GI, Via Natural or Artificial Opening

• 3E0H77Z - Introduction of Electrolytic and Water Balance Substance into Lower GI, Via Natural or Artificial Opening

• 3E0H7BZ - Introduction of Anesthetic Agent into Lower GI, Via Natural or Artificial Opening

• 3E0H7GC - Introduction of Other Therapeutic Substance into Lower GI, Via Natural or Artificial Opening

• 3E0H7HZ - Introduction of Radioactive Substance into Lower GI, Via Natural or Artificial Opening

• 3E0H7KZ - Introduction of Other Diagnostic Substance into Lower GI, Via Natural or Artificial Opening

• 3E0H7NZ - Introduction of Analgesics, Hypnotics, Sedatives into Lower GI, Via Natural or Artificial Opening

• 3E0H7SF - Introduction of Other Gas into Lower GI, Via Natural or Artificial Opening

• 3E0H7TZ - Introduction of Destructive Agent into Lower GI, Via Natural or Artificial Opening

• 3E0H804 - Introduction of Liquid Brachytherapy Radioisotope into Lower GI, Via Natural or Artificial Opening Endoscopic

• 3E0H805 - Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening Endoscopic

• 3E0H80M - Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening Endoscopic

• 3E0H828 - Introduction of Oxazolidinones into Lower GI, Via Natural or Artificial Opening Endoscopic

• 3E0H829 - Introduction of Other Anti-infective into Lower GI, Via Natural or Artificial Opening Endoscopic

• 3E0H83Z - Introduction of Anti-inflammatory into Lower GI, Via Natural or Artificial Opening Endoscopic

• 3E0H86Z - Introduction of Nutritional Substance into Lower GI, Via Natural or Artificial Opening Endoscopic

• 3E0H87Z - Introduction of Electrolytic and Water Balance Substance into Lower GI, Via Natural or Artificial Opening Endoscopic

• 3E0H8BZ - Introduction of Anesthetic Agent into Lower GI, Via Natural or Artificial Opening Endoscopic

• 3E0H8GC - Introduction of Other Therapeutic Substance into Lower GI, Via Natural or Artificial Opening Endoscopic

• 3E0H8HZ - Introduction of Radioactive Substance into Lower GI, Via Natural or Artificial Opening Endoscopic

• 3E0H8KZ - Introduction of Other Diagnostic Substance into Lower GI, Via Natural or Artificial Opening Endoscopic

• 3E0H8NZ - Introduction of Analgesics, Hypnotics, Sedatives into Lower GI, Via Natural or Artificial Opening Endoscopic

• 3E0H8SF - Introduction of Other Gas into Lower GI, Via Natural or Artificial Opening Endoscopic

• 3E0H8TZ - Introduction of Destructive Agent into Lower GI, Via Natural or Artificial Opening Endoscopic

• 3E0J304 - Introduction of Liquid Brachytherapy Radioisotope into Biliary and Pancreatic Tract, Percutaneous Approach

• 3E0J305 - Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Percutaneous Approach

• 3E0J30M - Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Percutaneous Approach

• 3E0J328 - Introduction of Oxazolidinones into Biliary and Pancreatic Tract, Percutaneous Approach

• 3E0J329 - Introduction of Other Anti-infective into Biliary and Pancreatic Tract, Percutaneous Approach

• 3E0J33Z - Introduction of Anti-inflammatory into Biliary and Pancreatic Tract, Percutaneous Approach

• 3E0J36Z - Introduction of Nutritional Substance into Biliary and Pancreatic Tract, Percutaneous Approach

• 3E0J37Z - Introduction of Electrolytic and Water Balance Substance into Biliary and Pancreatic Tract, Percutaneous Approach

• 3E0J3BZ - Introduction of Anesthetic Agent into Biliary and Pancreatic Tract, Percutaneous Approach

• 3E0J3GC - Introduction of Other Therapeutic Substance into Biliary and Pancreatic Tract, Percutaneous Approach

• 3E0J3HZ - Introduction of Radioactive Substance into Biliary and Pancreatic Tract, Percutaneous Approach

• 3E0J3KZ - Introduction of Other Diagnostic Substance into Biliary and Pancreatic Tract, Percutaneous Approach

• 3E0J3NZ - Introduction of Analgesics, Hypnotics, Sedatives into Biliary and Pancreatic Tract, Percutaneous Approach

• 3E0J3SF - Introduction of Other Gas into Biliary and Pancreatic Tract, Percutaneous Approach

• 3E0J3TZ - Introduction of Destructive Agent into Biliary and Pancreatic Tract, Percutaneous Approach

• 3E0J3U0 - Introduction of Autologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Percutaneous Approach

• 3E0J3U1 - Introduction of Nonautologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Percutaneous Approach

• 3E0J4GC - Introduction of Other Therapeutic Substance into Biliary and Pancreatic Tract, Percutaneous Endoscopic Approach

• 3E0J704 - Introduction of Liquid Brachytherapy Radioisotope into Biliary and Pancreatic Tract, Via Natural or Artificial Opening

• 3E0J705 - Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening

• 3E0J70M - Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Openin...

• 3E0J728 - Introduction of Oxazolidinones into Biliary and Pancreatic Tract, Via Natural or Artificial Opening

• 3E0J729 - Introduction of Other Anti-infective into Biliary and Pancreatic Tract, Via Natural or Artificial Opening

• 3E0J73Z - Introduction of Anti-inflammatory into Biliary and Pancreatic Tract, Via Natural or Artificial Opening

• 3E0J76Z - Introduction of Nutritional Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening

• 3E0J77Z - Introduction of Electrolytic and Water Balance Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Op...

• 3E0J7BZ - Introduction of Anesthetic Agent into Biliary and Pancreatic Tract, Via Natural or Artificial Opening

• 3E0J7GC - Introduction of Other Therapeutic Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening

• 3E0J7HZ - Introduction of Radioactive Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening

• 3E0J7KZ - Introduction of Other Diagnostic Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening

• 3E0J7NZ - Introduction of Analgesics, Hypnotics, Sedatives into Biliary and Pancreatic Tract, Via Natural or Artificial Opening

• 3E0J7SF - Introduction of Other Gas into Biliary and Pancreatic Tract, Via Natural or Artificial Opening

• 3E0J7TZ - Introduction of Destructive Agent into Biliary and Pancreatic Tract, Via Natural or Artificial Opening

• 3E0J7U0 - Introduction of Autologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Opening

• 3E0J7U1 - Introduction of Nonautologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Openin...

• 3E0J804 - Introduction of Liquid Brachytherapy Radioisotope into Biliary and Pancreatic Tract, Via Natural or Artificial Opening E...

• 3E0J805 - Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic

• 3E0J80M - Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Openin...

• 3E0J828 - Introduction of Oxazolidinones into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic

• 3E0J829 - Introduction of Other Anti-infective into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic

• 3E0J83Z - Introduction of Anti-inflammatory into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic

• 3E0J86Z - Introduction of Nutritional Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic

• 3E0J87Z - Introduction of Electrolytic and Water Balance Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Op...

• 3E0J8BZ - Introduction of Anesthetic Agent into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic

• 3E0J8GC - Introduction of Other Therapeutic Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endosco...

• 3E0J8HZ - Introduction of Radioactive Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic

• 3E0J8KZ - Introduction of Other Diagnostic Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscop...

• 3E0J8NZ - Introduction of Analgesics, Hypnotics, Sedatives into Biliary and Pancreatic Tract, Via Natural or Artificial Opening En...

• 3E0J8SF - Introduction of Other Gas into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic

• 3E0J8TZ - Introduction of Destructive Agent into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic

• 3E0J8U0 - Introduction of Autologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Opening E...

• 3E0J8U1 - Introduction of Nonautologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Openin...

• 3E0K304 - Introduction of Liquid Brachytherapy Radioisotope into Genitourinary Tract, Percutaneous Approach

• 3E0K305 - Introduction of Other Antineoplastic into Genitourinary Tract, Percutaneous Approach

• 3E0K30M - Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Percutaneous Approach

• 3E0K328 - Introduction of Oxazolidinones into Genitourinary Tract, Percutaneous Approach

• 3E0K329 - Introduction of Other Anti-infective into Genitourinary Tract, Percutaneous Approach

• 3E0K33Z - Introduction of Anti-inflammatory into Genitourinary Tract, Percutaneous Approach

• 3E0K36Z - Introduction of Nutritional Substance into Genitourinary Tract, Percutaneous Approach

• 3E0K37Z - Introduction of Electrolytic and Water Balance Substance into Genitourinary Tract, Percutaneous Approach

• 3E0K3BZ - Introduction of Anesthetic Agent into Genitourinary Tract, Percutaneous Approach

• 3E0K3GC - Introduction of Other Therapeutic Substance into Genitourinary Tract, Percutaneous Approach

• 3E0K3HZ - Introduction of Radioactive Substance into Genitourinary Tract, Percutaneous Approach

• 3E0K3KZ - Introduction of Other Diagnostic Substance into Genitourinary Tract, Percutaneous Approach

• 3E0K3NZ - Introduction of Analgesics, Hypnotics, Sedatives into Genitourinary Tract, Percutaneous Approach

• 3E0K3SF - Introduction of Other Gas into Genitourinary Tract, Percutaneous Approach

• 3E0K3TZ - Introduction of Destructive Agent into Genitourinary Tract, Percutaneous Approach

• 3E0K4GC - Introduction of Other Therapeutic Substance into Genitourinary Tract, Percutaneous Endoscopic Approach

• 3E0K704 - Introduction of Liquid Brachytherapy Radioisotope into Genitourinary Tract, Via Natural or Artificial Opening

• 3E0K705 - Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening

• 3E0K70M - Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening

• 3E0K728 - Introduction of Oxazolidinones into Genitourinary Tract, Via Natural or Artificial Opening

• 3E0K729 - Introduction of Other Anti-infective into Genitourinary Tract, Via Natural or Artificial Opening

• 3E0K73Z - Introduction of Anti-inflammatory into Genitourinary Tract, Via Natural or Artificial Opening

• 3E0K76Z - Introduction of Nutritional Substance into Genitourinary Tract, Via Natural or Artificial Opening

• 3E0K77Z - Introduction of Electrolytic and Water Balance Substance into Genitourinary Tract, Via Natural or Artificial Opening

• 3E0K7BZ - Introduction of Anesthetic Agent into Genitourinary Tract, Via Natural or Artificial Opening

• 3E0K7GC - Introduction of Other Therapeutic Substance into Genitourinary Tract, Via Natural or Artificial Opening

• 3E0K7HZ - Introduction of Radioactive Substance into Genitourinary Tract, Via Natural or Artificial Opening

• 3E0K7KZ - Introduction of Other Diagnostic Substance into Genitourinary Tract, Via Natural or Artificial Opening

• 3E0K7NZ - Introduction of Analgesics, Hypnotics, Sedatives into Genitourinary Tract, Via Natural or Artificial Opening

• 3E0K7SF - Introduction of Other Gas into Genitourinary Tract, Via Natural or Artificial Opening

• 3E0K7TZ - Introduction of Destructive Agent into Genitourinary Tract, Via Natural or Artificial Opening

• 3E0K804 - Introduction of Liquid Brachytherapy Radioisotope into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic

• 3E0K805 - Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic

• 3E0K80M - Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening Endosco...

• 3E0K828 - Introduction of Oxazolidinones into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic

• 3E0K829 - Introduction of Other Anti-infective into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic

• 3E0K83Z - Introduction of Anti-inflammatory into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic

• 3E0K86Z - Introduction of Nutritional Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic

• 3E0K87Z - Introduction of Electrolytic and Water Balance Substance into Genitourinary Tract, Via Natural or Artificial Opening End...

• 3E0K8BZ - Introduction of Anesthetic Agent into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic

• 3E0K8GC - Introduction of Other Therapeutic Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic

• 3E0K8HZ - Introduction of Radioactive Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic

• 3E0K8KZ - Introduction of Other Diagnostic Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic

• 3E0K8NZ - Introduction of Analgesics, Hypnotics, Sedatives into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic

• 3E0K8SF - Introduction of Other Gas into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic

• 3E0K8TZ - Introduction of Destructive Agent into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic

• 3E0L05Z - Introduction of Adhesion Barrier into Pleural Cavity, Open Approach

• 3E0L304 - Introduction of Liquid Brachytherapy Radioisotope into Pleural Cavity, Percutaneous Approach

• 3E0L305 - Introduction of Other Antineoplastic into Pleural Cavity, Percutaneous Approach

• 3E0L30M - Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Percutaneous Approach

• 3E0L317 - Introduction of Other Thrombolytic into Pleural Cavity, Percutaneous Approach

• 3E0L328 - Introduction of Oxazolidinones into Pleural Cavity, Percutaneous Approach

• 3E0L329 - Introduction of Other Anti-infective into Pleural Cavity, Percutaneous Approach

• 3E0L33Z - Introduction of Anti-inflammatory into Pleural Cavity, Percutaneous Approach

• 3E0L35Z - Introduction of Adhesion Barrier into Pleural Cavity, Percutaneous Approach

• 3E0L36Z - Introduction of Nutritional Substance into Pleural Cavity, Percutaneous Approach

• 3E0L37Z - Introduction of Electrolytic and Water Balance Substance into Pleural Cavity, Percutaneous Approach

• 3E0L3BZ - Introduction of Anesthetic Agent into Pleural Cavity, Percutaneous Approach

• 3E0L3GC - Introduction of Other Therapeutic Substance into Pleural Cavity, Percutaneous Approach

• 3E0L3HZ - Introduction of Radioactive Substance into Pleural Cavity, Percutaneous Approach

• 3E0L3KZ - Introduction of Other Diagnostic Substance into Pleural Cavity, Percutaneous Approach

• 3E0L3NZ - Introduction of Analgesics, Hypnotics, Sedatives into Pleural Cavity, Percutaneous Approach

• 3E0L3SF - Introduction of Other Gas into Pleural Cavity, Percutaneous Approach

• 3E0L3TZ - Introduction of Destructive Agent into Pleural Cavity, Percutaneous Approach

• 3E0L45Z - Introduction of Adhesion Barrier into Pleural Cavity, Percutaneous Endoscopic Approach

• 3E0L4GC - Introduction of Other Therapeutic Substance into Pleural Cavity, Percutaneous Endoscopic Approach

• 3E0L704 - Introduction of Liquid Brachytherapy Radioisotope into Pleural Cavity, Via Natural or Artificial Opening

• 3E0L705 - Introduction of Other Antineoplastic into Pleural Cavity, Via Natural or Artificial Opening

• 3E0L70M - Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Via Natural or Artificial Opening

• 3E0L7SF - Introduction of Other Gas into Pleural Cavity, Via Natural or Artificial Opening

• 3E0M05Z - Introduction of Adhesion Barrier into Peritoneal Cavity, Open Approach

• 3E0M304 - Introduction of Liquid Brachytherapy Radioisotope into Peritoneal Cavity, Percutaneous Approach

• 3E0M305 - Introduction of Other Antineoplastic into Peritoneal Cavity, Percutaneous Approach

• 3E0M30M - Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Percutaneous Approach

• 3E0M30Y - Introduction of Hyperthermic Antineoplastic into Peritoneal Cavity, Percutaneous Approach

• 3E0M328 - Introduction of Oxazolidinones into Peritoneal Cavity, Percutaneous Approach

• 3E0M329 - Introduction of Other Anti-infective into Peritoneal Cavity, Percutaneous Approach

• 3E0M33Z - Introduction of Anti-inflammatory into Peritoneal Cavity, Percutaneous Approach

• 3E0M35Z - Introduction of Adhesion Barrier into Peritoneal Cavity, Percutaneous Approach

• 3E0M36Z - Introduction of Nutritional Substance into Peritoneal Cavity, Percutaneous Approach

• 3E0M37Z - Introduction of Electrolytic and Water Balance Substance into Peritoneal Cavity, Percutaneous Approach

• 3E0M3BZ - Introduction of Anesthetic Agent into Peritoneal Cavity, Percutaneous Approach

• 3E0M3GC - Introduction of Other Therapeutic Substance into Peritoneal Cavity, Percutaneous Approach

• 3E0M3HZ - Introduction of Radioactive Substance into Peritoneal Cavity, Percutaneous Approach

• 3E0M3KZ - Introduction of Other Diagnostic Substance into Peritoneal Cavity, Percutaneous Approach

• 3E0M3NZ - Introduction of Analgesics, Hypnotics, Sedatives into Peritoneal Cavity, Percutaneous Approach

• 3E0M3SF - Introduction of Other Gas into Peritoneal Cavity, Percutaneous Approach

• 3E0M3TZ - Introduction of Destructive Agent into Peritoneal Cavity, Percutaneous Approach

• 3E0M45Z - Introduction of Adhesion Barrier into Peritoneal Cavity, Percutaneous Endoscopic Approach

• 3E0M4GC - Introduction of Other Therapeutic Substance into Peritoneal Cavity, Percutaneous Endoscopic Approach

• 3E0M704 - Introduction of Liquid Brachytherapy Radioisotope into Peritoneal Cavity, Via Natural or Artificial Opening

• 3E0M705 - Introduction of Other Antineoplastic into Peritoneal Cavity, Via Natural or Artificial Opening

• 3E0M70M - Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Via Natural or Artificial Opening

• 3E0M7SF - Introduction of Other Gas into Peritoneal Cavity, Via Natural or Artificial Opening

• 3E0N304 - Introduction of Liquid Brachytherapy Radioisotope into Male Reproductive, Percutaneous Approach

• 3E0N305 - Introduction of Other Antineoplastic into Male Reproductive, Percutaneous Approach

• 3E0N30M - Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Percutaneous Approach

• 3E0N328 - Introduction of Oxazolidinones into Male Reproductive, Percutaneous Approach

• 3E0N329 - Introduction of Other Anti-infective into Male Reproductive, Percutaneous Approach

• 3E0N33Z - Introduction of Anti-inflammatory into Male Reproductive, Percutaneous Approach

• 3E0N36Z - Introduction of Nutritional Substance into Male Reproductive, Percutaneous Approach

• 3E0N37Z - Introduction of Electrolytic and Water Balance Substance into Male Reproductive, Percutaneous Approach

• 3E0N3BZ - Introduction of Anesthetic Agent into Male Reproductive, Percutaneous Approach

• 3E0N3GC - Introduction of Other Therapeutic Substance into Male Reproductive, Percutaneous Approach

• 3E0N3HZ - Introduction of Radioactive Substance into Male Reproductive, Percutaneous Approach

• 3E0N3KZ - Introduction of Other Diagnostic Substance into Male Reproductive, Percutaneous Approach

• 3E0N3NZ - Introduction of Analgesics, Hypnotics, Sedatives into Male Reproductive, Percutaneous Approach

• 3E0N3SF - Introduction of Other Gas into Male Reproductive, Percutaneous Approach

• 3E0N3TZ - Introduction of Destructive Agent into Male Reproductive, Percutaneous Approach

• 3E0N4GC - Introduction of Other Therapeutic Substance into Male Reproductive, Percutaneous Endoscopic Approach

• 3E0N704 - Introduction of Liquid Brachytherapy Radioisotope into Male Reproductive, Via Natural or Artificial Opening

• 3E0N705 - Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening

• 3E0N70M - Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening

• 3E0N728 - Introduction of Oxazolidinones into Male Reproductive, Via Natural or Artificial Opening

• 3E0N729 - Introduction of Other Anti-infective into Male Reproductive, Via Natural or Artificial Opening

• 3E0N73Z - Introduction of Anti-inflammatory into Male Reproductive, Via Natural or Artificial Opening

• 3E0N76Z - Introduction of Nutritional Substance into Male Reproductive, Via Natural or Artificial Opening

• 3E0N77Z - Introduction of Electrolytic and Water Balance Substance into Male Reproductive, Via Natural or Artificial Opening

• 3E0N7BZ - Introduction of Anesthetic Agent into Male Reproductive, Via Natural or Artificial Opening

• 3E0N7GC - Introduction of Other Therapeutic Substance into Male Reproductive, Via Natural or Artificial Opening

• 3E0N7HZ - Introduction of Radioactive Substance into Male Reproductive, Via Natural or Artificial Opening

• 3E0N7KZ - Introduction of Other Diagnostic Substance into Male Reproductive, Via Natural or Artificial Opening

• 3E0N7NZ - Introduction of Analgesics, Hypnotics, Sedatives into Male Reproductive, Via Natural or Artificial Opening

• 3E0N7SF - Introduction of Other Gas into Male Reproductive, Via Natural or Artificial Opening

• 3E0N7TZ - Introduction of Destructive Agent into Male Reproductive, Via Natural or Artificial Opening

• 3E0N804 - Introduction of Liquid Brachytherapy Radioisotope into Male Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0N805 - Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0N80M - Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening Endoscopi...

• 3E0N828 - Introduction of Oxazolidinones into Male Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0N829 - Introduction of Other Anti-infective into Male Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0N83Z - Introduction of Anti-inflammatory into Male Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0N86Z - Introduction of Nutritional Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0N87Z - Introduction of Electrolytic and Water Balance Substance into Male Reproductive, Via Natural or Artificial Opening Endos...

• 3E0N8BZ - Introduction of Anesthetic Agent into Male Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0N8GC - Introduction of Other Therapeutic Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0N8HZ - Introduction of Radioactive Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0N8KZ - Introduction of Other Diagnostic Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0N8NZ - Introduction of Analgesics, Hypnotics, Sedatives into Male Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0N8SF - Introduction of Other Gas into Male Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0N8TZ - Introduction of Destructive Agent into Male Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0P05Z - Introduction of Adhesion Barrier into Female Reproductive, Open Approach

• 3E0P304 - Introduction of Liquid Brachytherapy Radioisotope into Female Reproductive, Percutaneous Approach

• 3E0P305 - Introduction of Other Antineoplastic into Female Reproductive, Percutaneous Approach

• 3E0P30M - Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Percutaneous Approach

• 3E0P328 - Introduction of Oxazolidinones into Female Reproductive, Percutaneous Approach

• 3E0P329 - Introduction of Other Anti-infective into Female Reproductive, Percutaneous Approach

• 3E0P33Z - Introduction of Anti-inflammatory into Female Reproductive, Percutaneous Approach

• 3E0P35Z - Introduction of Adhesion Barrier into Female Reproductive, Percutaneous Approach

• 3E0P36Z - Introduction of Nutritional Substance into Female Reproductive, Percutaneous Approach

• 3E0P37Z - Introduction of Electrolytic and Water Balance Substance into Female Reproductive, Percutaneous Approach

• 3E0P3BZ - Introduction of Anesthetic Agent into Female Reproductive, Percutaneous Approach

• 3E0P3GC - Introduction of Other Therapeutic Substance into Female Reproductive, Percutaneous Approach

• 3E0P3HZ - Introduction of Radioactive Substance into Female Reproductive, Percutaneous Approach

• 3E0P3KZ - Introduction of Other Diagnostic Substance into Female Reproductive, Percutaneous Approach

• 3E0P3LZ - Introduction of Sperm into Female Reproductive, Percutaneous Approach

• 3E0P3NZ - Introduction of Analgesics, Hypnotics, Sedatives into Female Reproductive, Percutaneous Approach

• 3E0P3Q0 - Introduction of Autologous Fertilized Ovum into Female Reproductive, Percutaneous Approach

• 3E0P3Q1 - Introduction of Nonautologous Fertilized Ovum into Female Reproductive, Percutaneous Approach

• 3E0P3SF - Introduction of Other Gas into Female Reproductive, Percutaneous Approach

• 3E0P3TZ - Introduction of Destructive Agent into Female Reproductive, Percutaneous Approach

• 3E0P3VZ - Introduction of Hormone into Female Reproductive, Percutaneous Approach

• 3E0P45Z - Introduction of Adhesion Barrier into Female Reproductive, Percutaneous Endoscopic Approach

• 3E0P4GC - Introduction of Other Therapeutic Substance into Female Reproductive, Percutaneous Endoscopic Approach

• 3E0P704 - Introduction of Liquid Brachytherapy Radioisotope into Female Reproductive, Via Natural or Artificial Opening

• 3E0P705 - Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening

• 3E0P70M - Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening

• 3E0P728 - Introduction of Oxazolidinones into Female Reproductive, Via Natural or Artificial Opening

• 3E0P729 - Introduction of Other Anti-infective into Female Reproductive, Via Natural or Artificial Opening

• 3E0P73Z - Introduction of Anti-inflammatory into Female Reproductive, Via Natural or Artificial Opening

• 3E0P76Z - Introduction of Nutritional Substance into Female Reproductive, Via Natural or Artificial Opening

• 3E0P77Z - Introduction of Electrolytic and Water Balance Substance into Female Reproductive, Via Natural or Artificial Opening

• 3E0P7BZ - Introduction of Anesthetic Agent into Female Reproductive, Via Natural or Artificial Opening

• 3E0P7GC - Introduction of Other Therapeutic Substance into Female Reproductive, Via Natural or Artificial Opening

• 3E0P7HZ - Introduction of Radioactive Substance into Female Reproductive, Via Natural or Artificial Opening

• 3E0P7KZ - Introduction of Other Diagnostic Substance into Female Reproductive, Via Natural or Artificial Opening

• 3E0P7LZ - Introduction of Sperm into Female Reproductive, Via Natural or Artificial Opening

• 3E0P7NZ - Introduction of Analgesics, Hypnotics, Sedatives into Female Reproductive, Via Natural or Artificial Opening

• 3E0P7Q0 - Introduction of Autologous Fertilized Ovum into Female Reproductive, Via Natural or Artificial Opening

• 3E0P7Q1 - Introduction of Nonautologous Fertilized Ovum into Female Reproductive, Via Natural or Artificial Opening

• 3E0P7SF - Introduction of Other Gas into Female Reproductive, Via Natural or Artificial Opening

• 3E0P7TZ - Introduction of Destructive Agent into Female Reproductive, Via Natural or Artificial Opening

• 3E0P7VZ - Introduction of Hormone into Female Reproductive, Via Natural or Artificial Opening

• 3E0P804 - Introduction of Liquid Brachytherapy Radioisotope into Female Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0P805 - Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0P80M - Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening Endosco...

• 3E0P828 - Introduction of Oxazolidinones into Female Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0P829 - Introduction of Other Anti-infective into Female Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0P83Z - Introduction of Anti-inflammatory into Female Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0P86Z - Introduction of Nutritional Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0P87Z - Introduction of Electrolytic and Water Balance Substance into Female Reproductive, Via Natural or Artificial Opening End...

• 3E0P8BZ - Introduction of Anesthetic Agent into Female Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0P8GC - Introduction of Other Therapeutic Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0P8HZ - Introduction of Radioactive Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0P8KZ - Introduction of Other Diagnostic Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0P8NZ - Introduction of Analgesics, Hypnotics, Sedatives into Female Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0P8SF - Introduction of Other Gas into Female Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0P8TZ - Introduction of Destructive Agent into Female Reproductive, Via Natural or Artificial Opening Endoscopic

• 3E0Q004 - Introduction of Liquid Brachytherapy Radioisotope into Cranial Cavity and Brain, Open Approach

• 3E0Q005 - Introduction of Other Antineoplastic into Cranial Cavity and Brain, Open Approach

• 3E0Q00M - Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Open Approach

• 3E0Q028 - Introduction of Oxazolidinones into Cranial Cavity and Brain, Open Approach

• 3E0Q029 - Introduction of Other Anti-infective into Cranial Cavity and Brain, Open Approach

• 3E0Q03Z - Introduction of Anti-inflammatory into Cranial Cavity and Brain, Open Approach

• 3E0Q06Z - Introduction of Nutritional Substance into Cranial Cavity and Brain, Open Approach

• 3E0Q07Z - Introduction of Electrolytic and Water Balance Substance into Cranial Cavity and Brain, Open Approach

• 3E0Q0AZ - Introduction of Embryonic Stem Cells into Cranial Cavity and Brain, Open Approach

• 3E0Q0BZ - Introduction of Anesthetic Agent into Cranial Cavity and Brain, Open Approach

• 3E0Q0E0 - Introduction of Autologous Somatic Stem Cells into Cranial Cavity and Brain, Open Approach

• 3E0Q0E1 - Introduction of Nonautologous Somatic Stem Cells into Cranial Cavity and Brain, Open Approach

• 3E0Q0GC - Introduction of Other Therapeutic Substance into Cranial Cavity and Brain, Open Approach

• 3E0Q0HZ - Introduction of Radioactive Substance into Cranial Cavity and Brain, Open Approach

• 3E0Q0KZ - Introduction of Other Diagnostic Substance into Cranial Cavity and Brain, Open Approach

• 3E0Q0NZ - Introduction of Analgesics, Hypnotics, Sedatives into Cranial Cavity and Brain, Open Approach

• 3E0Q0SF - Introduction of Other Gas into Cranial Cavity and Brain, Open Approach

• 3E0Q0TZ - Introduction of Destructive Agent into Cranial Cavity and Brain, Open Approach

• 3E0Q304 - Introduction of Liquid Brachytherapy Radioisotope into Cranial Cavity and Brain, Percutaneous Approach

• 3E0Q305 - Introduction of Other Antineoplastic into Cranial Cavity and Brain, Percutaneous Approach

• 3E0Q30M - Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Percutaneous Approach

• 3E0Q328 - Introduction of Oxazolidinones into Cranial Cavity and Brain, Percutaneous Approach

• 3E0Q329 - Introduction of Other Anti-infective into Cranial Cavity and Brain, Percutaneous Approach

• 3E0Q33Z - Introduction of Anti-inflammatory into Cranial Cavity and Brain, Percutaneous Approach

• 3E0Q36Z - Introduction of Nutritional Substance into Cranial Cavity and Brain, Percutaneous Approach

• 3E0Q37Z - Introduction of Electrolytic and Water Balance Substance into Cranial Cavity and Brain, Percutaneous Approach

• 3E0Q3AZ - Introduction of Embryonic Stem Cells into Cranial Cavity and Brain, Percutaneous Approach

• 3E0Q3BZ - Introduction of Anesthetic Agent into Cranial Cavity and Brain, Percutaneous Approach

• 3E0Q3E0 - Introduction of Autologous Somatic Stem Cells into Cranial Cavity and Brain, Percutaneous Approach

• 3E0Q3E1 - Introduction of Nonautologous Somatic Stem Cells into Cranial Cavity and Brain, Percutaneous Approach

• 3E0Q3GC - Introduction of Other Therapeutic Substance into Cranial Cavity and Brain, Percutaneous Approach

• 3E0Q3HZ - Introduction of Radioactive Substance into Cranial Cavity and Brain, Percutaneous Approach

• 3E0Q3KZ - Introduction of Other Diagnostic Substance into Cranial Cavity and Brain, Percutaneous Approach

• 3E0Q3NZ - Introduction of Analgesics, Hypnotics, Sedatives into Cranial Cavity and Brain, Percutaneous Approach

• 3E0Q3SF - Introduction of Other Gas into Cranial Cavity and Brain, Percutaneous Approach

• 3E0Q3TZ - Introduction of Destructive Agent into Cranial Cavity and Brain, Percutaneous Approach

• 3E0Q704 - Introduction of Liquid Brachytherapy Radioisotope into Cranial Cavity and Brain, Via Natural or Artificial Opening

• 3E0Q705 - Introduction of Other Antineoplastic into Cranial Cavity and Brain, Via Natural or Artificial Opening

• 3E0Q70M - Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Via Natural or Artificial Opening

• 3E0Q7SF - Introduction of Other Gas into Cranial Cavity and Brain, Via Natural or Artificial Opening

• 3E0R0AZ - Introduction of Embryonic Stem Cells into Spinal Canal, Open Approach

• 3E0R0E0 - Introduction of Autologous Somatic Stem Cells into Spinal Canal, Open Approach

• 3E0R0E1 - Introduction of Nonautologous Somatic Stem Cells into Spinal Canal, Open Approach

• 3E0R302 - Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach

• 3E0R303 - Introduction of Low-dose Interleukin-2 into Spinal Canal, Percutaneous Approach

• 3E0R304 - Introduction of Liquid Brachytherapy Radioisotope into Spinal Canal, Percutaneous Approach

• 3E0R305 - Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach

• 3E0R30M - Introduction of Antineoplastic, Monoclonal Antibody, into Spinal Canal, Percutaneous Approach

• 3E0R328 - Introduction of Oxazolidinones into Spinal Canal, Percutaneous Approach

• 3E0R329 - Introduction of Other Anti-infective into Spinal Canal, Percutaneous Approach

• 3E0R33Z - Introduction of Anti-inflammatory into Spinal Canal, Percutaneous Approach

• 3E0R36Z - Introduction of Nutritional Substance into Spinal Canal, Percutaneous Approach

• 3E0R37Z - Introduction of Electrolytic and Water Balance Substance into Spinal Canal, Percutaneous Approach

• 3E0R3AZ - Introduction of Embryonic Stem Cells into Spinal Canal, Percutaneous Approach

• 3E0R3BZ - Introduction of Anesthetic Agent into Spinal Canal, Percutaneous Approach

• 3E0R3E0 - Introduction of Autologous Somatic Stem Cells into Spinal Canal, Percutaneous Approach

• 3E0R3E1 - Introduction of Nonautologous Somatic Stem Cells into Spinal Canal, Percutaneous Approach

• 3E0R3GC - Introduction of Other Therapeutic Substance into Spinal Canal, Percutaneous Approach

• 3E0R3HZ - Introduction of Radioactive Substance into Spinal Canal, Percutaneous Approach

• 3E0R3KZ - Introduction of Other Diagnostic Substance into Spinal Canal, Percutaneous Approach

• 3E0R3NZ - Introduction of Analgesics, Hypnotics, Sedatives into Spinal Canal, Percutaneous Approach

• 3E0R3SF - Introduction of Other Gas into Spinal Canal, Percutaneous Approach

• 3E0R3TZ - Introduction of Destructive Agent into Spinal Canal, Percutaneous Approach

• 3E0R7SF - Introduction of Other Gas into Spinal Canal, Via Natural or Artificial Opening

• 3E0S302 - Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach

• 3E0S303 - Introduction of Low-dose Interleukin-2 into Epidural Space, Percutaneous Approach

• 3E0S304 - Introduction of Liquid Brachytherapy Radioisotope into Epidural Space, Percutaneous Approach

• 3E0S305 - Introduction of Other Antineoplastic into Epidural Space, Percutaneous Approach

• 3E0S30M - Introduction of Antineoplastic, Monoclonal Antibody, into Epidural Space, Percutaneous Approach

• 3E0S328 - Introduction of Oxazolidinones into Epidural Space, Percutaneous Approach

• 3E0S329 - Introduction of Other Anti-infective into Epidural Space, Percutaneous Approach

• 3E0S33Z - Introduction of Anti-inflammatory into Epidural Space, Percutaneous Approach

• 3E0S36Z - Introduction of Nutritional Substance into Epidural Space, Percutaneous Approach

• 3E0S37Z - Introduction of Electrolytic and Water Balance Substance into Epidural Space, Percutaneous Approach

• 3E0S3BZ - Introduction of Anesthetic Agent into Epidural Space, Percutaneous Approach

• 3E0S3GC - Introduction of Other Therapeutic Substance into Epidural Space, Percutaneous Approach

• 3E0S3HZ - Introduction of Radioactive Substance into Epidural Space, Percutaneous Approach

• 3E0S3KZ - Introduction of Other Diagnostic Substance into Epidural Space, Percutaneous Approach

• 3E0S3NZ - Introduction of Analgesics, Hypnotics, Sedatives into Epidural Space, Percutaneous Approach

• 3E0S3SF - Introduction of Other Gas into Epidural Space, Percutaneous Approach

• 3E0S3TZ - Introduction of Destructive Agent into Epidural Space, Percutaneous Approach

• 3E0S7SF - Introduction of Other Gas into Epidural Space, Via Natural or Artificial Opening

• 3E0T33Z - Introduction of Anti-inflammatory into Peripheral Nerves and Plexi, Percutaneous Approach

• 3E0T3BZ - Introduction of Anesthetic Agent into Peripheral Nerves and Plexi, Percutaneous Approach

• 3E0T3GC - Introduction of Other Therapeutic Substance into Peripheral Nerves and Plexi, Percutaneous Approach

• 3E0T3TZ - Introduction of Destructive Agent into Peripheral Nerves and Plexi, Percutaneous Approach

• 3E0U028 - Introduction of Oxazolidinones into Joints, Open Approach

• 3E0U029 - Introduction of Other Anti-infective into Joints, Open Approach

• 3E0U0GB - Introduction of Recombinant Bone Morphogenetic Protein into Joints, Open Approach

• 3E0U304 - Introduction of Liquid Brachytherapy Radioisotope into Joints, Percutaneous Approach

• 3E0U305 - Introduction of Other Antineoplastic into Joints, Percutaneous Approach

• 3E0U30M - Introduction of Antineoplastic, Monoclonal Antibody, into Joints, Percutaneous Approach

• 3E0U328 - Introduction of Oxazolidinones into Joints, Percutaneous Approach

• 3E0U329 - Introduction of Other Anti-infective into Joints, Percutaneous Approach

• 3E0U33Z - Introduction of Anti-inflammatory into Joints, Percutaneous Approach

• 3E0U36Z - Introduction of Nutritional Substance into Joints, Percutaneous Approach

• 3E0U37Z - Introduction of Electrolytic and Water Balance Substance into Joints, Percutaneous Approach

• 3E0U3BZ - Introduction of Anesthetic Agent into Joints, Percutaneous Approach

• 3E0U3GB - Introduction of Recombinant Bone Morphogenetic Protein into Joints, Percutaneous Approach

• 3E0U3GC - Introduction of Other Therapeutic Substance into Joints, Percutaneous Approach

• 3E0U3HZ - Introduction of Radioactive Substance into Joints, Percutaneous Approach

• 3E0U3KZ - Introduction of Other Diagnostic Substance into Joints, Percutaneous Approach

• 3E0U3NZ - Introduction of Analgesics, Hypnotics, Sedatives into Joints, Percutaneous Approach

• 3E0U3SF - Introduction of Other Gas into Joints, Percutaneous Approach

• 3E0U3TZ - Introduction of Destructive Agent into Joints, Percutaneous Approach

• 3E0U4GC - Introduction of Other Therapeutic Substance into Joints, Percutaneous Endoscopic Approach

• 3E0V0GB - Introduction of Recombinant Bone Morphogenetic Protein into Bones, Open Approach

• 3E0V0GC - Introduction of Other Therapeutic Substance into Bones, Open Approach

• 3E0V305 - Introduction of Other Antineoplastic into Bones, Percutaneous Approach

• 3E0V30M - Introduction of Antineoplastic, Monoclonal Antibody, into Bones, Percutaneous Approach

• 3E0V328 - Introduction of Oxazolidinones into Bones, Percutaneous Approach

• 3E0V329 - Introduction of Other Anti-infective into Bones, Percutaneous Approach

• 3E0V33Z - Introduction of Anti-inflammatory into Bones, Percutaneous Approach

• 3E0V36Z - Introduction of Nutritional Substance into Bones, Percutaneous Approach

• 3E0V37Z - Introduction of Electrolytic and Water Balance Substance into Bones, Percutaneous Approach

• 3E0V3BZ - Introduction of Anesthetic Agent into Bones, Percutaneous Approach

• 3E0V3GB - Introduction of Recombinant Bone Morphogenetic Protein into Bones, Percutaneous Approach

• 3E0V3GC - Introduction of Other Therapeutic Substance into Bones, Percutaneous Approach

• 3E0V3HZ - Introduction of Radioactive Substance into Bones, Percutaneous Approach

• 3E0V3KZ - Introduction of Other Diagnostic Substance into Bones, Percutaneous Approach

• 3E0V3NZ - Introduction of Analgesics, Hypnotics, Sedatives into Bones, Percutaneous Approach

• 3E0V3TZ - Introduction of Destructive Agent into Bones, Percutaneous Approach

• 3E0V4GC - Introduction of Other Therapeutic Substance into Bones, Percutaneous Endoscopic Approach

• 3E0W305 - Introduction of Other Antineoplastic into Lymphatics, Percutaneous Approach

• 3E0W30M - Introduction of Antineoplastic, Monoclonal Antibody, into Lymphatics, Percutaneous Approach

• 3E0W328 - Introduction of Oxazolidinones into Lymphatics, Percutaneous Approach

• 3E0W329 - Introduction of Other Anti-infective into Lymphatics, Percutaneous Approach

• 3E0W33Z - Introduction of Anti-inflammatory into Lymphatics, Percutaneous Approach

• 3E0W36Z - Introduction of Nutritional Substance into Lymphatics, Percutaneous Approach

• 3E0W37Z - Introduction of Electrolytic and Water Balance Substance into Lymphatics, Percutaneous Approach

• 3E0W3BZ - Introduction of Anesthetic Agent into Lymphatics, Percutaneous Approach

• 3E0W3GC - Introduction of Other Therapeutic Substance into Lymphatics, Percutaneous Approach

• 3E0W3HZ - Introduction of Radioactive Substance into Lymphatics, Percutaneous Approach

• 3E0W3KZ - Introduction of Other Diagnostic Substance into Lymphatics, Percutaneous Approach

• 3E0W3NZ - Introduction of Analgesics, Hypnotics, Sedatives into Lymphatics, Percutaneous Approach

• 3E0W3TZ - Introduction of Destructive Agent into Lymphatics, Percutaneous Approach

• 3E0X33Z - Introduction of Anti-inflammatory into Cranial Nerves, Percutaneous Approach

• 3E0X3BZ - Introduction of Anesthetic Agent into Cranial Nerves, Percutaneous Approach

• 3E0X3GC - Introduction of Other Therapeutic Substance into Cranial Nerves, Percutaneous Approach

• 3E0X3TZ - Introduction of Destructive Agent into Cranial Nerves, Percutaneous Approach

• 3E0Y304 - Introduction of Liquid Brachytherapy Radioisotope into Pericardial Cavity, Percutaneous Approach

• 3E0Y305 - Introduction of Other Antineoplastic into Pericardial Cavity, Percutaneous Approach

• 3E0Y30M - Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Percutaneous Approach

• 3E0Y328 - Introduction of Oxazolidinones into Pericardial Cavity, Percutaneous Approach

• 3E0Y329 - Introduction of Other Anti-infective into Pericardial Cavity, Percutaneous Approach

• 3E0Y33Z - Introduction of Anti-inflammatory into Pericardial Cavity, Percutaneous Approach

• 3E0Y36Z - Introduction of Nutritional Substance into Pericardial Cavity, Percutaneous Approach

• 3E0Y37Z - Introduction of Electrolytic and Water Balance Substance into Pericardial Cavity, Percutaneous Approach

• 3E0Y3BZ - Introduction of Anesthetic Agent into Pericardial Cavity, Percutaneous Approach

• 3E0Y3GC - Introduction of Other Therapeutic Substance into Pericardial Cavity, Percutaneous Approach

• 3E0Y3HZ - Introduction of Radioactive Substance into Pericardial Cavity, Percutaneous Approach

• 3E0Y3KZ - Introduction of Other Diagnostic Substance into Pericardial Cavity, Percutaneous Approach

• 3E0Y3NZ - Introduction of Analgesics, Hypnotics, Sedatives into Pericardial Cavity, Percutaneous Approach

• 3E0Y3SF - Introduction of Other Gas into Pericardial Cavity, Percutaneous Approach

• 3E0Y3TZ - Introduction of Destructive Agent into Pericardial Cavity, Percutaneous Approach

• 3E0Y4GC - Introduction of Other Therapeutic Substance into Pericardial Cavity, Percutaneous Endoscopic Approach

• 3E0Y704 - Introduction of Liquid Brachytherapy Radioisotope into Pericardial Cavity, Via Natural or Artificial Opening

• 3E0Y705 - Introduction of Other Antineoplastic into Pericardial Cavity, Via Natural or Artificial Opening

• 3E0Y70M - Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Via Natural or Artificial Opening

• 3E0Y7SF - Introduction of Other Gas into Pericardial Cavity, Via Natural or Artificial Opening